<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="review-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Front Behav Neurosci</journal-id>
<journal-id journal-id-type="iso-abbrev">Front Behav Neurosci</journal-id>
<journal-id journal-id-type="publisher-id">Front. Behav. Neurosci.</journal-id>
<journal-title-group>
<journal-title>Frontiers in Behavioral Neuroscience</journal-title>
</journal-title-group>
<issn pub-type="epub">1662-5153</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">28979198</article-id>
<article-id pub-id-type="pmc">5611489</article-id>
<article-id pub-id-type="doi">10.3389/fnbeh.2017.00181</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Neuroscience</subject>
<subj-group>
<subject>Review</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Schizophrenia: What’s Arc Got to Do with It?</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Managò</surname>
<given-names>Francesca</given-names>
</name>
<uri xlink:href="http://loop.frontiersin.org/people/451584/overview" xlink:type="simple"></uri>
<xref ref-type="aff" rid="aff1"></xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Papaleo</surname>
<given-names>Francesco</given-names>
</name>
<xref ref-type="author-notes" rid="fn001">
<sup>*</sup>
</xref>
<uri xlink:href="http://loop.frontiersin.org/people/358773/overview" xlink:type="simple"></uri>
<xref ref-type="aff" rid="aff1"></xref>
</contrib>
</contrib-group>
<aff id="aff1"><institution>Department of Neuroscience and Brain Technologies, Istituto Italiano di Tecnologia</institution>
<country>Genova, Italy</country></aff>
<author-notes>
<fn fn-type="edited-by">
<p>Edited by: Amelia Gallitano, University of Arizona, United States</p>
</fn>
<fn fn-type="edited-by">
<p>Reviewed by: Clive R. Bramham, University of Bergen, Norway; Tsuyoshi Miyakawa, Fujita Health University, Japan</p>
</fn>
<corresp id="fn001">*Correspondence: Francesco Papaleo <email xlink:type="simple">francesco.papaleo@iit.it</email></corresp>
</author-notes>
<pub-date pub-type="epub">
<day>20</day>
<month>9</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="collection">
<year>2017</year>
</pub-date>
<volume>11</volume>
<elocation-id>181</elocation-id>
<history>
<date date-type="received">
<day>01</day>
<month>5</month>
<year>2017</year>
</date>
<date date-type="accepted">
<day>11</day>
<month>9</month>
<year>2017</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright © 2017 Managò and Papaleo.</copyright-statement>
<copyright-year>2017</copyright-year>
<copyright-holder>Managò and Papaleo</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p>
</license>
</permissions>
<abstract>
<p>Human studies of schizophrenia are now reporting a previously unidentified genetic convergence on postsynaptic signaling complexes such as the activity-regulated cytoskeletal-associated (Arc) gene. However, because this evidence is still very recent, the neurobiological implication of Arc in schizophrenia is still scattered and unrecognized. Here, we first review current and developing findings connecting Arc in schizophrenia. We then highlight recent and previous findings from preclinical mouse models that elucidate how Arc genetic modifications might recapitulate schizophrenia-relevant behavioral phenotypes following the novel Research Domain Criteria (RDoC) framework. Building on this, we finally compare and evaluate several lines of evidence demonstrating that Arc genetics can alter both glutamatergic and dopaminergic systems in a very selective way, again consistent with molecular alterations characteristic of schizophrenia. Despite being only initial, accumulating and compelling data are showing that Arc might be one of the primary biological players in schizophrenia. Synaptic plasticity alterations in the genetic architecture of psychiatric disorders might be a rule, not an exception. Thus, we anticipate that additional evidence will soon emerge to clarify the Arc-dependent mechanisms involved in the psychiatric-related dysfunctional behavior.</p>
</abstract>
<kwd-group>
<kwd>behavior</kwd>
<kwd>RDoC</kwd>
<kwd>dopamine</kwd>
<kwd>glutamate</kwd>
<kwd>immediate early gene</kwd>
<kwd>Arg3.1</kwd>
<kwd>mice</kwd>
</kwd-group>
<counts>
<fig-count count="1"></fig-count>
<table-count count="0"></table-count>
<equation-count count="0"></equation-count>
<ref-count count="123"></ref-count>
<page-count count="11"></page-count>
<word-count count="9658"></word-count>
</counts>
</article-meta>
</front>
<body>
<sec id="s1">
<title>Schizophrenia</title>
<p>Neuropsychiatric disorders are still defined by an ensemble of different behavioral abnormalities appearing with a certain intensity and duration that strongly disrupt the normal life of the affected individuals (American Psychiatric Association, <xref ref-type="bibr" rid="B3">2013</xref>). However, these behavioral alterations present huge heterogeneity within and between subjects in terms of intensity, timing, penetrance depending on the sex and age of the subjects as well as assessment by different health care providers and responses to treatments. “Schizophrenia spectrum and other psychotic disorders” is a definition given when clinical features categorized as positive (e.g., delusions, hallucinations, disorganized thinking, grossly disorganized or abnormal motor behavior) and negative symptoms (e.g., diminished emotional expression and avolition) are evident in an individual (Lewis and Gonzalez-Burgos, <xref ref-type="bibr" rid="B60">2006</xref>; American Psychiatric Association, <xref ref-type="bibr" rid="B3">2013</xref>). In addition, cognitive deficits, mainly in executive functions, are long-lasting traits in patients diagnosed with schizophrenia and constitute key prognostic factors for the long-term outcomes of the disease such as the level of functional capability, social and occupational ability and quality of life (Green, <xref ref-type="bibr" rid="B40">1996</xref>; Green and Nuechterlein, <xref ref-type="bibr" rid="B41">1999</xref>; Mueser and McGurk, <xref ref-type="bibr" rid="B81">2004</xref>). Thus, it is clear that such a complex disorder uniquely defined by several different behavioral abnormalities is subject to different degrees of heterogeneity.</p>
<p>Consistent evidence indicates that many psychiatric disorders such as schizophrenia have a strong genetic contributing factor with heritability estimated at up to 80% (Cardno and Gottesman, <xref ref-type="bibr" rid="B20">2000</xref>; Sullivan et al., <xref ref-type="bibr" rid="B107">2003</xref>). Because of this, over the last decade, an increasing effort has been made to disentangle the possible impact of genetics in the development and heterogeneity of schizophrenia and of psychiatric disorders in general (Fromer et al., <xref ref-type="bibr" rid="B33">2014</xref>; Purcell et al., <xref ref-type="bibr" rid="B93">2014</xref>; O’Donovan and Owen, <xref ref-type="bibr" rid="B87">2016</xref>). Despite other factors being implicated (e.g., environmental, epigenetics etc.), the current hope in advanced genetic assessments is to improve the causal understanding of psychiatric disorders, to provide a better definition of them, and to ultimately identify better and more effective treatments.</p>
</sec>
<sec id="s2">
<title>Arc Genetics in Schizophrenia</title>
<p>Thanks to recent improvements in genomic sequencing techniques, Fromer et al. (<xref ref-type="bibr" rid="B33">2014</xref>) were able to run an exome sequencing study scanning genes for the <italic>de novo</italic> mutation at the single-base resolution on genomic DNA of 623 schizophrenia proband trios. Furthermore, Purcell et al. (<xref ref-type="bibr" rid="B93">2014</xref>), focusing on a subset of almost 2500 genes that have been previously implicated in schizophrenia, have sequenced the currently largest sample of patients with schizophrenia (2536) and healthy controls (2543). Both these works have unexpectedly revealed a consistent convergence of genetic variations on a set of synaptic proteins that interact with the activity-regulated cytoskeleton associated protein (Arc; Fromer et al., <xref ref-type="bibr" rid="B33">2014</xref>; Purcell et al., <xref ref-type="bibr" rid="B93">2014</xref>). For example, among the 28 genes listed in the “Arc complex”, it has been proven that Arc protein directly binds Wave1, GKAP, IQSEC2, GluNA2 (Myrum et al., <xref ref-type="bibr" rid="B82">2015a</xref>; Zhang et al., <xref ref-type="bibr" rid="B122">2015</xref>). However, further biochemical experiments should be performed to substantiate and better validate the mechanisms of interaction within this Arc complex. Nevertheless, in the same year, another study reported reduced expression of Arc mRNA in the prefrontal cortex (PFC) of individuals with schizophrenia (Guillozet-Bongaarts et al., <xref ref-type="bibr" rid="B44">2014</xref>). Moreover, an investigation on variants within the Arc gene reported a direct association between the rs35900184 single-nucleotide polymorphism (SNP) and schizophrenia (Huentelman et al., <xref ref-type="bibr" rid="B50">2015</xref>). To further support the possible implication of Arc in the pathophysiology of schizophrenia, the copy number variance (CNV) and schizophrenia working groups of psychiatric genomics consortium analyzed the CNV of the entire genome comparing more than 40,000 individuals among patients and healthy controls. Again, deletions in a subset of genes belonging to the Arc complex were significantly enriched in patients with schizophrenia (Marshall et al., <xref ref-type="bibr" rid="B24">2017</xref>). Finally, different mouse models relevant to schizophrenia show reduced Arc expression, which is instead not evident in mouse models relevant to other psychiatric disorders such as ADHD or bipolar disorders (Matsuo et al., <xref ref-type="bibr" rid="B69">2009</xref>; Takao et al., <xref ref-type="bibr" rid="B110">2013</xref>; Takagi et al., <xref ref-type="bibr" rid="B109">2015</xref>; Managò et al., <xref ref-type="bibr" rid="B66">2016</xref>; Chen et al., <xref ref-type="bibr" rid="B21">2017</xref>; Mereu et al., <xref ref-type="bibr" rid="B72">2017</xref>). This might suggest that the Arc pathway may serve as a hub that functionally links numerous schizophrenia risk-related factors. Together, these findings point to a previously undetected association of the immediate early gene (IEG) Arc to schizophrenia. However, Arc causal implication in the neuropathophysiology of schizophrenia is just starting to be elucidated (following paragraphs).</p>
</sec>
<sec id="s3">
<title>Arc Genetics in Behavior</title>
<p>Psychiatric disorders, including schizophrenia, are characterized by abnormal behaviors. Thus, here we will first address the implication of Arc genetics in behavioral functions. In particular, we will follow the new Research Domain Criteria (RDoC) framework recently developed by the USA National Institutes of Health (NIH/NIMH, <xref ref-type="bibr" rid="B86">2017</xref>). The RDoC system currently includes five distinct domains: (1) Cognitive Systems. (2) Systems for Social Processes. (3) Positive Valence System. (4) Negative Valence Systems. (5) Arousal/Regulatory Systems). The RDoC framework aim to integrate many levels of information (from genomics to self-report) with specific dimensions of behavioral functioning, overcoming the boundaries of mental diagnosis. Indeed, within a disease as defined by DSM-V, alterations of different brain circuits or neurotransmitters could affect the same behavior. Alternatively, in different psychiatric illnesses, the same biological alteration could lead to a common behavioral alteration.</p>
<p>To our knowledge, there are still no selective Arc genetic variations in humans proven to be functional (i.e., altering Arc mRNA and/or protein expression). Only one study reported a case of a 7-year old female with a 540 kb microdeletion in the 8q24.3 region, which included Arc but also several other genes (Hu et al., <xref ref-type="bibr" rid="B49">2015</xref>). This patient showed developmental abnormalities, Intellectual Disabilities (ID), autism and attention deficit hyperactive disorder (ADHD). Similarly, the mother, who carried the same microdeletion, presented a milder phenotype, including learning disabilities, depression, panic disorder and obsessive tendencies (Hu et al., <xref ref-type="bibr" rid="B49">2015</xref>). However, this microdeletion syndrome does not account for the selective impact of Arc genetic disruption in behavioral abnormalities. Due to the lack of human data on functional common genetic alterations selective for Arc, our discussion will be centered on the available information derived from preclinical studies addressing the impact of selective Arc functional genetic variations in behavioral functioning.</p>
</sec>
<sec id="s4">
<title>Cognitive Systems</title>
<p>Arc genetic variations were initially implicated in the formation of long-term memories. Indeed, compared to wild-type mice, Arc knockouts performed slightly worse in the spatial Morris water maze, were impaired in contextual and cued fear conditioning, showed reduced conditioned taste aversion, and impaired long-term novel object recognition memory (Plath et al., <xref ref-type="bibr" rid="B91">2006</xref>). All these abnormal cognitive functions suggest that reduced levels of Arc might be related to hippocampus-dependent memory deficits. Indeed, blocking the expression of Arc selectively in the hippocampus produced the same pattern of performance in the above mentioned tasks, including reduced spatial and fear memory formation in the Morris water maze and fear conditioning task (Guzowski et al., <xref ref-type="bibr" rid="B45">2000</xref>; Chia and Otto, <xref ref-type="bibr" rid="B22">2013</xref>; Nakayama et al., <xref ref-type="bibr" rid="B84">2015</xref>). Altered long-term memories might be present in patients with schizophrenia (Goldberg et al., <xref ref-type="bibr" rid="B39">1989</xref>; Aleman et al., <xref ref-type="bibr" rid="B2">1999</xref>; Ranganath et al., <xref ref-type="bibr" rid="B94">2008</xref>), even if this is not considered a signature feature. For example, patients with schizophrenia might present episodic memory deficits due to an altered pattern of hippocampal-PFC activity, but they do not show an amnesic syndrome (Ranganath et al., <xref ref-type="bibr" rid="B94">2008</xref>). More recently, we found that partial and complete deletion of the Arc gene in mice produced recency memory deficits in the temporal order object recognition task as well as spatial memory deficits in the spatial object recognition task (Managò et al., <xref ref-type="bibr" rid="B66">2016</xref>). In contrast, cognitive abilities assessed by a recent-memory novel object recognition task reported to be dependent uniquely on the perirhinal cortex (PRH; Barker et al., <xref ref-type="bibr" rid="B7">2007</xref>) were intact (Managò et al., <xref ref-type="bibr" rid="B66">2016</xref>). These findings parallel similar evidence from patients with schizophrenia who show impairments in temporal context memory related to objects as well as in spatial navigation, while no alterations are evident in the ability to recall and recognize target items (Schwartz et al., <xref ref-type="bibr" rid="B100">1991</xref>; Rizzo et al., <xref ref-type="bibr" rid="B97">1996</xref>; Dreher et al., <xref ref-type="bibr" rid="B28">2001</xref>; Folley et al., <xref ref-type="bibr" rid="B31">2010</xref>). These recent mouse studies (Managò et al., <xref ref-type="bibr" rid="B66">2016</xref>) begin to suggest that Arc-dependent cognitive abnormalities might rely on altered PFC and hippocampal dysfunction in the context of a normal functioning of the PRH. In agreement, convergent genetic, molecular, clinical, neurophysiological, neuropsychological and imaging work confirmed the presence of an altered pattern of PFC and hippocampal activation in schizophrenia (Meyer-Lindenberg and Weinberger, <xref ref-type="bibr" rid="B74">2006</xref>; Papaleo et al., <xref ref-type="bibr" rid="B89">2012</xref>; Millan et al., <xref ref-type="bibr" rid="B75">2014</xref>). Initial work did not find an association between Arc common genetic variants and general cognitive abilities in healthy subjects (Myrum et al., <xref ref-type="bibr" rid="B83">2015b</xref>). However, the Arc genetic variations investigated were not shown to have a functional impact on Arc protein or mRNA expression. Thus, future studies will be needed in order to disentangle the selective implication of Arc functional genetic variations in working memory performance and executive functions, the two cognitive domains at the basis of schizophrenia neuropathophysiology.</p>
</sec>
<sec id="s5">
<title>Systems for Social Processes</title>
<p>In recent years, there has been growing consensus that abnormalities in social cognition form part of the core symptoms in schizophrenia (Billeke and Aboitiz, <xref ref-type="bibr" rid="B11">2013</xref>; Millan et al., <xref ref-type="bibr" rid="B75">2014</xref>). Individuals with schizophrenia have marked impairments in processing non-verbal social affective information while showing normal affect sharing and emotion experience (Green et al., <xref ref-type="bibr" rid="B42">2015</xref>). Notably, social cognitive impairments in these individuals have a more deleterious impact on daily functioning than non-social cognitive deficits (Fett et al., <xref ref-type="bibr" rid="B30">2011</xref>). Arc knockout mice show impaired social abilities as demonstrated by reduced sociability and reduced preference for social novelty (Managò et al., <xref ref-type="bibr" rid="B66">2016</xref>). In particular, in the 3-chamber paradigm, Arc knockout mice preferred to be in the chamber with an empty cup rather than with a novel conspecific. Moreover, Arc knockout mice were not able to discriminate between a novel and a familiar conspecific. These social measures were obtained in a well-established test for mice used to assess social avoidance and preference for social novelty (Moy et al., <xref ref-type="bibr" rid="B79">2004</xref>, <xref ref-type="bibr" rid="B80">2008</xref>). Decreased interaction with conspecifics is an index of social withdrawal reminiscent of what is observed in patients with schizophrenia. Indeed, low social reciprocity with others and deficits in social cognition (Harvey et al., <xref ref-type="bibr" rid="B47">2006</xref>) are core features of schizophrenia negative symptomatology. Moreover, these symptoms are also enduring and less responsive to medication, not to mention among the most disabling features of this psychiatric illness. Therefore, the reduced sociability and preference for social novelty shown by Arc knockout mice is consistent with the deficits seen in patients with schizophrenia and represent further evidence supporting the role of reduced Arc levels in schizophrenia neuropathology. However, we should highlight that despite their extensive use and importance, currently available tasks assessing social functions in rodents are still limited in their equivalence to tasks used in the human clinical setting. Indeed, social cognitive processes such as theory of mind, facial perception/recognition, and emotion regulation are the social processes mostly impaired in schizophrenia (Green et al., <xref ref-type="bibr" rid="B42">2015</xref>). These social cognitive functions are not yet directly and specifically testable in rodents. This will require consistent efforts in the field with a clear aim to prove the predictive translational validity of novel and more refined social cognitive tasks in rodents.</p>
</sec>
<sec id="s6">
<title>Positive Valence System</title>
<p>This domain involves processes such as motivation, responsiveness to reward and habit formation. In schizophrenia, the hedonic responses to reward and willingness to work for a reward (motivational state) are impaired (Gard et al., <xref ref-type="bibr" rid="B37">2009</xref>). Unfortunately, as far as we know, there is little evidence demonstrating that genetic variations in Arc play a role in these processes. However, recent work has begun to address this domain. One study reported that Arc knockout mice develop a cocaine-conditioned place preference (Salery et al., <xref ref-type="bibr" rid="B98">2017</xref>), at doses that are ineffective in wild-type mice (Contarino et al., <xref ref-type="bibr" rid="B25">2017</xref>). This suggest that Arc genetic disruption might increase rewarding effects of psychostimulant drugs, but further work will be needed in this novel and interesting area of research.</p>
</sec>
<sec id="s7">
<title>Negative Valence Systems</title>
<p>No alterations in anxiety-like states have been found in Arc knockout mice as measured by the O-maze and light-dark tests (Plath et al., <xref ref-type="bibr" rid="B91">2006</xref>). Similarly, reactivity to acute threats such as mild foot shocks (Plath et al., <xref ref-type="bibr" rid="B91">2006</xref>) or sudden acoustic sensory stimuli (Managò et al., <xref ref-type="bibr" rid="B66">2016</xref>) was not altered in Arc knockout mice. However, overall Arc genetic disruption as well as knocking down Arc expression selectively in the lateral amygdala was enough to produce a deficit in fear conditioning memories (Ploski et al., <xref ref-type="bibr" rid="B92">2008</xref>). Thus, these data suggest a marginal role of Arc genetic variations in the negative valence domain, with more direct involvement in the storage and expression of aversive memories.</p>
</sec>
<sec id="s8">
<title>Arousal/Regulatory Systems</title>
<p>This domain includes processes responsible for generating activation of neural systems as appropriate for various contexts, and providing appropriate homeostatic regulation (subcategories: arousal, circadian rhythms and sleep/wakefulness). Arousal represent the time of perception of internal/external stimuli related to the coding of relevant vs. non-relevant stimuli of the environment. Hippocampal CA1 recordings of local field potential during locomotion revealed a reduced power in the gamma and beta-2 range in Arc knockout mice compared to wild-type, indicating a disruption in the neuronal synchronization during active behavior (Malkki et al., <xref ref-type="bibr" rid="B65">2016</xref>). In agreement, Arc knockout mice show altered activity when exposed to a newly-presented environment. In particular, both a slightly hyperactive (Managò et al., <xref ref-type="bibr" rid="B66">2016</xref>) or hypoactive (Salery et al., <xref ref-type="bibr" rid="B98">2017</xref>) phenotype have been reported. However, it is worth noting that the experimental setting of the latter study might have produced misleading and less sensitive data in locomotor activity as it was based on the breaking of only four beams placed at 90 degree points of a circular corridor. More consistent instead, Arc knockout mice showed increased locomotor sensitivity to dopaminergic psychostimulants including amphetamine (Managò et al., <xref ref-type="bibr" rid="B66">2016</xref>) and cocaine (Salery et al., <xref ref-type="bibr" rid="B98">2017</xref>). Moreover, repeated exposure to amphetamine produce, in the dorsal striatum and nucleus accumbens, a selective increase in a subset of mRNAs including Arc (Biever et al., <xref ref-type="bibr" rid="B10">2017</xref>). Finally, the psychostimulant-induced increase in Arc expression seems to be evident mostly in D1-positive medium spiny neurons as well as in NMDA-positive neurons in striatal regions (Biever et al., <xref ref-type="bibr" rid="B10">2017</xref>; Salery et al., <xref ref-type="bibr" rid="B98">2017</xref>). Overall, these evidence point to Arc as an integrator of D1 and NMDA signaling and demonstrate that Arc genetic disruption causes a predisposition to higher sensitivity to psychostimulants.</p>
<p>Psychostimulant super-sensitivity is used as a rodent correlate of schizophrenia-like positive symptoms (Arguello and Gogos, <xref ref-type="bibr" rid="B5">2006</xref>; van den Buuse, <xref ref-type="bibr" rid="B112">2010</xref>) and is relevant to the arousal domain of the RDoC system. In particular, amphetamine exacerbates psychotic experiences in patients with schizophrenia and can be psychotogenic in normal subjects (Laruelle et al., <xref ref-type="bibr" rid="B58">1999</xref>). Thus, Arc knockout mutants’ locomotor activity phenotypes are consistent with an increased arousal state to external stimuli and might be seen as a proxy of schizophrenia-like positive symptoms. Possibly due to different arousal states, Arc knockout mice also show prepulse-inhibition (PPI) deficits (Managò et al., <xref ref-type="bibr" rid="B66">2016</xref>). PPI is considered a measure of sensorimotor gating consistently conserved from rodents to humans (Braff and Geyer, <xref ref-type="bibr" rid="B14">1990</xref>). There have been numerous reports of PPI deficits in patients with schizophrenia (Swerdlow et al., <xref ref-type="bibr" rid="B108">2008</xref>), their unaffected first degree relatives (Cadenhead et al., <xref ref-type="bibr" rid="B17">1993</xref>, <xref ref-type="bibr" rid="B18">2000</xref>), and patients with schizotypal personality disorder (Cadenhead et al., <xref ref-type="bibr" rid="B17">1993</xref>). Thus, the PPI deficits in Arc knockout mice are consistent with a schizophrenia-relevant behavioral endophenotype.</p>
<p>Related to sleep processes instead, initial studies reported that Arc knockout mice do not show any differences in the composition of sleep (Malkki et al., <xref ref-type="bibr" rid="B65">2016</xref>). This suggest a marginal implication of Arc genetics in relationship to sleep and wakefulness, and a negligible implication of “off-line” processing (e.g., during post-behavioral sleep) in cognitive deficits.</p>
</sec>
<sec id="s9">
<title>Arc Biology</title>
<p>Arc is only present in Ca<sup>2+</sup>/Calmodulin-dependent kinase II alpha (CaMKIIa) expressing neurons in the hippocampus, neocortex and striatum (Vazdarjanova et al., <xref ref-type="bibr" rid="B113">2006</xref>; Miyashita et al., <xref ref-type="bibr" rid="B77">2008</xref>). Its expression is tightly regulated. Indeed, after a novel experience, Arc mRNA moves to the dendrites in the active synapse where is translated (Link et al., <xref ref-type="bibr" rid="B63">1995</xref>; Lyford et al., <xref ref-type="bibr" rid="B64">1995</xref>; Jakkamsetti et al., <xref ref-type="bibr" rid="B52">2013</xref>). Here, Arc protein plays a critical role in long-lasting forms of synaptic plasticity, including long-term potentiation (LTP), long-term depression (LTD) and homeostatic scaling (Plath et al., <xref ref-type="bibr" rid="B91">2006</xref>; Rial Verde et al., <xref ref-type="bibr" rid="B96">2006</xref>; Shepherd et al., <xref ref-type="bibr" rid="B102">2006</xref>; Park et al., <xref ref-type="bibr" rid="B90">2008</xref>; Waung et al., <xref ref-type="bibr" rid="B115">2008</xref>; Jakkamsetti et al., <xref ref-type="bibr" rid="B52">2013</xref>). Thus, Arc might be considered as an integrator of different inputs coming from the nervous system in order to lead to a proper synaptic connection. In particular, Arc might work as a downstream regulator, and functional Arc genetic variations might represent a direct genetic bridge between different schizophrenia-related signaling systems. In this context, we will discuss possible molecular mechanisms of Arc in the modulation of glutamatergic and dopaminergic pathways, two systems extensively implicated in the schizophrenia neuropathology.</p>
</sec>
<sec id="s10">
<title>Arc and Glutamate</title>
<p>Arc has been consistently linked to the glutamatergic system and reduced Arc protein expression alter glutamate-mediated processes such as learning and memory formation, cognition and neuronal plasticity (Guzowski et al., <xref ref-type="bibr" rid="B45">2000</xref>; Park et al., <xref ref-type="bibr" rid="B90">2008</xref>; Jakkamsetti et al., <xref ref-type="bibr" rid="B52">2013</xref>; Wang et al., <xref ref-type="bibr" rid="B114">2016</xref>). In particular, when Arc protein translation is disrupted, a high-frequency burst in the hippocampus is able to induce LTP; however, the second phase of consolidation of synaptic LTP is disrupted (Guzowski et al., <xref ref-type="bibr" rid="B45">2000</xref>). In agreement, Arc has a fundamental role in the stabilization of actin filament at the synaptic site (Messaoudi et al., <xref ref-type="bibr" rid="B73">2007</xref>). Moreover, Arc is implicated in the synaptic scaling of AMPA receptors for the induction of LTD, interacting with dynamin and endophilin (Chowdhury et al., <xref ref-type="bibr" rid="B23">2006</xref>). In particular, Arc facilitates the endocytosis of AMPA receptor, a process that is implicated in the induction of LTD (Chowdhury et al., <xref ref-type="bibr" rid="B23">2006</xref>; Shepherd et al., <xref ref-type="bibr" rid="B102">2006</xref>). Notably, Arc can accumulate also at the inactive synapses binding to the inactive form of CamKIIbeta, consequently leading to the endocytosis of AMPA receptors (Okuno et al., <xref ref-type="bibr" rid="B88">2012</xref>). Arc-dependent synaptic plasticity (LTP and LTD) is induced by the activation of mGluR1 or R5 (mGluR type I; Park et al., <xref ref-type="bibr" rid="B90">2008</xref>; Kumar et al., <xref ref-type="bibr" rid="B56">2012</xref>; Wang et al., <xref ref-type="bibr" rid="B114">2016</xref>), and requires the involvement of eEF2 and FMRP that are implicated in the translation of Arc mRNA to protein (Park et al., <xref ref-type="bibr" rid="B90">2008</xref>; Wang et al., <xref ref-type="bibr" rid="B114">2016</xref>). However, despite the established involvement of Arc in mGluR-dependent plasticity (Park et al., <xref ref-type="bibr" rid="B90">2008</xref>; Waung et al., <xref ref-type="bibr" rid="B115">2008</xref>), its role in NMDA-dependent plasticity is still controversial. For instance, the localization of Arc mRNA at active synapses on the dendrites requires NMDA activation (Steward and Worley, <xref ref-type="bibr" rid="B106">2001</xref>; Bloomer et al., <xref ref-type="bibr" rid="B12">2008</xref>). Furthermore, consolidation of memories leads to an increased Arc protein level (Guzowski et al., <xref ref-type="bibr" rid="B45">2000</xref>; McIntyre et al., <xref ref-type="bibr" rid="B71">2005</xref>), and blocking NMDA receptor reduced Arc expression induced by a learning process (Czerniawski et al., <xref ref-type="bibr" rid="B27">2011</xref>). However, other evidence indicate that NMDA-induced LTP or LTD is Arc-independent (Park et al., <xref ref-type="bibr" rid="B90">2008</xref>; Waung et al., <xref ref-type="bibr" rid="B115">2008</xref>). More recently, Arc was involved in experience-induced cortical firing patterns correlated with Arc-dependent increase of NMDA activity (Ren et al., <xref ref-type="bibr" rid="B95">2014</xref>). Overall, these findings highlight the importance of Arc in the consolidation of some types of NMDA-dependent memory formation. Thus, when Arc functioning is diminished, NMDA-dependent signaling is expected to be partially disrupted.</p>
<p>The glutamatergic system has been often implicated in the manifestation of schizophrenia-relevant clinical symptoms. Noncompetitive NMDA/glutamate receptor antagonists such as PCP, ketamine or MK801 have psychomimetic effects (Halberstadt, <xref ref-type="bibr" rid="B46">1995</xref>; Andiné et al., <xref ref-type="bibr" rid="B4">1999</xref>; Frohlich and Van Horn, <xref ref-type="bibr" rid="B32">2014</xref>) reproducing many behavioral alterations reminiscent of positive, negative and cognitive symptoms of schizophrenia in healthy humans and exaggerating positive and negative symptoms in patients with schizophrenia (Coyle, <xref ref-type="bibr" rid="B26">2006</xref>; Kantrowitz and Javitt, <xref ref-type="bibr" rid="B54">2010</xref>). Moreover, from recent genome-wide association studies (GWAS), several genes belonging to the glutamatergic system were part of the 108 list of implicated loci (Schizophrenia Working Group of the Psychiatric Genomics Consortium, <xref ref-type="bibr" rid="B99">2014</xref>). In particular, genes that encode subunits of NMDA and AMPA receptors were significantly coming out as being strongly implicated (Schizophrenia Working Group of the Psychiatric Genomics Consortium, <xref ref-type="bibr" rid="B99">2014</xref>). In agreement, a number of pre-clinical studies in rodents reported that an alteration of NMDA or AMPA transmission might recapitulate different behavioral alterations in a number of RDoC domains that might possibly be related to schizophrenia-relevant endophenotypes (Wiedholz et al., <xref ref-type="bibr" rid="B117">2008</xref>; Papaleo et al., <xref ref-type="bibr" rid="B89">2012</xref>). Despite this, and the consequent remarkable effort of the academics and the industry, clinical results related to new treatments for schizophrenia targeting the glutamatergic system have been disappointing (Iwata et al., <xref ref-type="bibr" rid="B51">2015</xref>; Bugarski-Kirola et al., <xref ref-type="bibr" rid="B16">2016</xref>). In this context, Arc being a downstream effector of glutamatergic receptors, it might be a better target and a more consistent cause of the development of schizophrenia-relevant behavioral alterations.</p>
</sec>
<sec id="s11">
<title>Arc and Dopamine</title>
<p>The long-standing pathophysiological hypothesis of schizophrenia involves a dysregulated dopaminergic system (Weinstein et al., <xref ref-type="bibr" rid="B116">2017</xref>). In particular, the current hypothesis highlights that a hyperactive mesolimbic system through an aberrant activation of D2 receptors might be more related to the so-called “positive symptoms”. Instead, a hypoactive mesocortical dopaminergic system with a lower stimulation of D1 receptor in the PFC can lead to schizophrenia negative and cognitive symptoms (Winterer and Weinberger, <xref ref-type="bibr" rid="B119">2004</xref>; Simpson et al., <xref ref-type="bibr" rid="B103">2010</xref>; Slifstein et al., <xref ref-type="bibr" rid="B104">2015</xref>). Notably, the most common first-line treatments for acute and chronic therapy for schizophrenia are antipsychotic drugs, all of which interact with dopamine/D2 receptors (D2) brain pathways (Miyamoto et al., <xref ref-type="bibr" rid="B76">2005</xref>; Hasan et al., <xref ref-type="bibr" rid="B48">2013</xref>). Finally, D2 receptors have been confirmed as one of the major schizophrenia-association genetic hits in the most recent GWAS studies (Schizophrenia Working Group of the Psychiatric Genomics Consortium, <xref ref-type="bibr" rid="B99">2014</xref>).</p>
<p>Up until last year, there has been no evidence implicating Arc genetic variations as modulators of the dopaminergic system. Indeed, the only data available were those reporting changes in Arc expression induced by dopamine agonists or antagonists as just a marker for neuronal activity (Moro et al., <xref ref-type="bibr" rid="B78">2007</xref>; Banerjee et al., <xref ref-type="bibr" rid="B6">2009</xref>; Fumagalli et al., <xref ref-type="bibr" rid="B34">2009</xref>). In contrast, we have now demonstrated that Arc genetic disruption result in selective alterations on different aspects of the dopaminergic system. In particular, Arc knockout mice have reduced amphetamine-induced dopamine release within the medial PFC (mPFC) and, in agreement, two-photon calcium imaging revealed a reduced mPFC activation following electrical stimulation of the ventral tegmental area (VTA; Managò et al., <xref ref-type="bibr" rid="B66">2016</xref>). Treatment with a D1 agonist rescued the altered mPFC activity as well as recency memory deficits, demonstrating that the mPFC hypofunction was D1-dependent (Managò et al., <xref ref-type="bibr" rid="B66">2016</xref>). Alternatively, infusing the D2 antagonist eticlopride directly into the nucleus accumbens of Arc knockout mice rescued their supersensitivity to amphetamine in terms of dopamine release and locomotor activity, unraveling a D2-dependent hyperactive dopaminergic mesolimbic system (Managò et al., <xref ref-type="bibr" rid="B66">2016</xref>). These Arc-dependent effects were evident in the mPFC and in the nucleus accumbens, but not in the dorsal striatum. The source of dopamine in both the mPFC and nucleus accumbens is the VTA, while in the dorsal striatum it is the substantia nigra (Beckstead et al., <xref ref-type="bibr" rid="B8">1979</xref>). Furthermore, amphetamine injection in Arc knockout mice produced opposing dopamine-release phenotypes in the mPFC compared to that in the nucleus accumbens. These contrasting effects in mesocortical and mesostriatal dopaminergic pathways might then suggest an Arc-dependent circuital dysfunction that will require further investigations. In conclusion, Arc function seems to be crucial for establishing a proper activity balance between mesocortical and mesostriatal dopaminergic circuits. Importantly, these alterations are reversible by selectively targeting D2 receptors in the ventral striatal regions and D1 receptors in the PFC.</p>
<p>Despite this previously unexpected evidence, the mechanisms underlying the peculiar effects of Arc genetics in the dopaminergic system are as yet unclear. Previous studies have reported that PFC dopaminergic inputs show protracted postnatal maturation through adolescence and are susceptible to activity-dependent modification during this period (Kalsbeek et al., <xref ref-type="bibr" rid="B53">1988</xref>; Lewis and O’Donnell, <xref ref-type="bibr" rid="B59">2000</xref>; Mastwal et al., <xref ref-type="bibr" rid="B68">2014</xref>). Recurrent network activity in frontal-striatal loops can also affect striatal circuit maturation (Kozorovitskiy et al., <xref ref-type="bibr" rid="B55">2012</xref>). As Arc protein is abundantly expressed in cortical excitatory and striatal GABAergic projection neurons (but not detected in midbrain dopamine neurons; Shepherd and Bear, <xref ref-type="bibr" rid="B101">2011</xref>), it may regulate activity-dependent maturation of the VTA-PFC-striatal circuits during postnatal development. Considering the well-known role of Arc in modulating glutamate receptors (Shepherd and Bear, <xref ref-type="bibr" rid="B101">2011</xref>; Jakkamsetti et al., <xref ref-type="bibr" rid="B52">2013</xref>; Ren et al., <xref ref-type="bibr" rid="B95">2014</xref>), and the balance between the glutamatergic and dopaminergic systems which tightly regulate each other, our recent findings raise the possibility that Arc-dependent changes in glutamatergic signaling might be the effector of the changes in the dopamine system. However, further studies are needed to unravel these issues and how Arc alterations at the single-cell level might affect these circuits.</p>
</sec>
<sec id="s12">
<title>Beyond Schizophrenia</title>
<p>Findings from genetics studies might be applied to discrete behavioral domains (e.g., RDoC framework) overcoming the boundaries of psychiatric diagnosis. The current system for diagnosing psychiatric illnesses, based on DSM guidelines, relies on defining a constellation of signs and symptoms, each of which may be present in a number of different disorders, and none of which is, by itself, diagnostic. In support of this idea, recent findings indicate that different psychiatric disorders such as schizophrenia, autism, ADHD, intellectual disability and bipolar disorder, might share common genetic variations (McCarthy et al., <xref ref-type="bibr" rid="B70">2014</xref>; Goes et al., <xref ref-type="bibr" rid="B38">2016</xref>; Zhao and Nyholt, <xref ref-type="bibr" rid="B123">2017</xref>). In this context, and because of its major modulatory impact in synaptic plasticity (Tzingounis and Nicoll, <xref ref-type="bibr" rid="B111">2006</xref>; Bloomer et al., <xref ref-type="bibr" rid="B12">2008</xref>; Park et al., <xref ref-type="bibr" rid="B90">2008</xref>; Waung et al., <xref ref-type="bibr" rid="B115">2008</xref>; Bramham et al., <xref ref-type="bibr" rid="B15">2010</xref>; Gao et al., <xref ref-type="bibr" rid="B35">2010</xref>; Ren et al., <xref ref-type="bibr" rid="B95">2014</xref>; Wang et al., <xref ref-type="bibr" rid="B114">2016</xref>), a role of Arc genetics in a number of different neurological and psychiatric disorders is not surprising (Greer et al., <xref ref-type="bibr" rid="B43">2010</xref>; Cao et al., <xref ref-type="bibr" rid="B19">2013</xref>; Ebert and Greenberg, <xref ref-type="bibr" rid="B29">2013</xref>; Li et al., <xref ref-type="bibr" rid="B62">2015</xref>). Indeed, Fromer et al. (<xref ref-type="bibr" rid="B33">2014</xref>) found that schizophrenia, autism spectrum disorder and ID share common genetic variations in the Arc complex. Despite this, to date, there have been no studies directly associating Arc genetic variations in other psychiatric disorders beyond schizophrenia. However, as already mentioned, one case with a rare microdeletion (8q24.3) encompassing the Arc gene demonstrated autistic traits, ID and ADHD (Hu et al., <xref ref-type="bibr" rid="B49">2015</xref>). Moreover, genetic modifications associated with different syndromes such as the fragile X, Angelman and Autism Spectrum Disorder concern genes that encode for proteins involved in the regulation of Arc expression (Smith et al., <xref ref-type="bibr" rid="B105">2011</xref>; Niere et al., <xref ref-type="bibr" rid="B85">2012</xref>; Cao et al., <xref ref-type="bibr" rid="B19">2013</xref>).</p>
<p>Patients with the Fragile X Syndrome (FXS) carry a triplet repeat expansion in the FMR1 gene that lead to reduced translation of the FMRP protein (Garber et al., <xref ref-type="bibr" rid="B36">2008</xref>). The FMRP is a protein synthesis regulator and one of its targets is Arc (Park et al., <xref ref-type="bibr" rid="B90">2008</xref>). In agreement, FMR1 knockout mice display higher production of Arc and consequent abnormal LTD (Niere et al., <xref ref-type="bibr" rid="B85">2012</xref>; Ebert and Greenberg, <xref ref-type="bibr" rid="B29">2013</xref>). The FXS is characterized by social impairments, cognitive disabilities, mood disorders and hyperactivity (Garber et al., <xref ref-type="bibr" rid="B36">2008</xref>), which are all behavioral domains affected by Arc genetic variations (see above). Thus, it might be plausible that altered Arc expression is one of the causes of these behavioral abnormalities.</p>
<p>The Angelman Syndrome (AS) is caused by the deletion or inactivation of the maternal copy of the Ube3a gene (Williams et al., <xref ref-type="bibr" rid="B118">2010</xref>). The <italic>Ube3a</italic> gene encodes for a brain-specific E3 ubiquitin ligase which has Arc as one of its substrates. In agreement, loss of Ube3A in mice cause an increase in Arc levels (Cao et al., <xref ref-type="bibr" rid="B19">2013</xref>). The core symptoms of this pathology are delayed motor milestones, mental retardation, seizures, movement or balance disorders (Williams et al., <xref ref-type="bibr" rid="B118">2010</xref>), once again asserting a potential implication of Arc-dependent mechanisms. Similarly, a genetic variation characterized by the appearance of Ube3A extra copies have also been associated with the autism spectrum disorder (Smith et al., <xref ref-type="bibr" rid="B105">2011</xref>). Indeed, patients with this mutation present impaired social and communication deficits as well as repetitive behaviors (Smith et al., <xref ref-type="bibr" rid="B105">2011</xref>; Bourgeron, <xref ref-type="bibr" rid="B13">2015</xref>). Similarly, transgenic mice with three copies of the Ube3A manifest social deficits and increased self-grooming compared to the control group. Moreover, this mutation produced an impairment in the glutamatergic transmission and decreased Arc availability (Smith et al., <xref ref-type="bibr" rid="B105">2011</xref>). Because these pathologies share common behavioral alterations in cognitive and social functions modulated by Arc genetics, we might hypothesize Arc as a converging downstream signaling output.</p>
<p>Finally, it seems that Arc could be involved also in Alzheimer’s disease (AD). Indeed, Arc can directly bind presenilin1 to regulate γ-secretase activity in order to form more β-amyloid peptides, participating in the formation of neuritic plaques. Furthermore, the same study has reported increased Arc protein levels in patients with AD (Wu et al., <xref ref-type="bibr" rid="B120">2011</xref>). Despite the potential direct role of Arc in the formation of β-amyloid peptides, both increased (Wu et al., <xref ref-type="bibr" rid="B120">2011</xref>) and decreased (Bi et al., <xref ref-type="bibr" rid="B9">2017</xref>) Arc expression have been reported in the cortex of patients with AD. Moreover, initial GWAS on European and American subjects did not reveal any association between Arc genetic variation and AD (Lambert et al., <xref ref-type="bibr" rid="B57">2013</xref>). Nonetheless, a more recent study has described a possible association of a SNP (rs10097505) in the 3’UTR of the Arc gene with susceptibility to AD (Bi et al., <xref ref-type="bibr" rid="B9">2017</xref>). Thus, further work will be needed to understand the possible involvement of Arc genetics in the AD pathology and especially in its cognitive manifestations.</p>
</sec>
<sec id="s13">
<title>Conclusions and Future Directions</title>
<p>The evidence discussed here highlight the consistent implication of Arc genetic variations in the development and manifestation of a number of behavioral abnormalities relevant to schizophrenia and other psychiatric disorders. In particular, mouse studies indicate a preponderant role of Arc in behavioral domains including cognitive, social and arousal processes, which might depend on the alterations of the glutamatergic and dopaminergic systems (Figure <xref ref-type="fig" rid="F1">1</xref>).</p>
<fig id="F1" position="float">
<label>Figure 1</label>
<caption>
<p>Activity-regulated cytoskeletal-associated (Arc)-dependent effects in Research Domain Criteria (RDoC) behavioral domains and its putative role in psychiatric disorders. Arc genetic disruption have been reported to alter both the dopaminergic and glutamatergic systems in a very selective way. This Arc-dependent altered neurotransmission results in deleterious effects in different behaviors. In particular, following the RDoC framework (NIH/NIMH, <xref ref-type="bibr" rid="B86">2017</xref>), altered levels of Arc induce consistent impairments mainly in cognitive systems, but also in social processes and in arousal/regulatory systems. More investigations are needed for the positive valence system. No major influence seems to be evident for the negative valence system. Ultimately, Arc-dependent alterations in these behavioral processes might converge in a pathological state. In agreement, genetic variations suggested to alter Arc expression have been implicated in different diseases such as Schizophrenia (Schizophrenia), Autism (ASD), Intellectual Disabilities (ID), Fragile X Syndrome (FXS), Angelman Syndrome (AS) and Alzheimer’s Disease (AD).</p>
</caption>
<graphic xlink:href="fnbeh-11-00181-g0001"></graphic>
</fig>
<p>Despite this, it is still unknown how disruption of Arc can recapitulate so divergent and selective alterations in the dopaminergic system. For example, it is not clear if the cause of the dopamine system dysfunction is driven by Arc disruption of the glutamatergic signaling or if Arc might exert a direct influence on dopaminergic pathways. Furthermore, it is still unclear if Arc might play a role in behavior directly altering it or through developmental processes or both. This will be particularly relevant as early detection and early intervention of cognitive and social deficits could be potentially more effective in mitigating the pathological trajectories and ultimately the life quality of individuals with schizophrenia-vulnerability. In this context, mouse models will be useful tools in the development and testing of early diagnosis and early treatment strategies, at the same time strictly controlling for environmental and genetic factors. An aberrant maturation of the PFC has been reported in schizophrenia (Lewis and Levitt, <xref ref-type="bibr" rid="B61">2002</xref>) and it is well known that the final maturation of dopaminergic terminals in the PFC is only reached after puberty (Manitt et al., <xref ref-type="bibr" rid="B67">2011</xref>). Arc mRNA expression starts to increase after postnatal day 7 in the cortex, and its activation depends on the correct dopaminergic input coming from the VTA (Ye et al., <xref ref-type="bibr" rid="B121">2016</xref>). Thus, we might hypothesize that this dopamine-induced Arc expression during postnatal development could be important for the correct establishment of synaptic connectivity within the mesocortical circuit. However, we cannot exclude an involvement of Arc in the prenatal developmental process as the presence of Arc in the brain has been detected since embryonic stages (Alberi et al., <xref ref-type="bibr" rid="B1">2011</xref>). Identifying the developmental functions of Arc would also be relevant to other neurodevelopmental disorders such as autism, FXS and AS as discussed above. Therefore, studying the role of Arc in brain development will be important.</p>
<p>In conclusion, a concerted effort between clinical and preclinical genetic and mechanistic studies focused on Arc modulation of behavioral outputs looks to be a promising area of investigation. Indeed, this could greatly advance our knowledge on the causes of schizophrenia, especially in the areas of cognitive and social alterations. Notably, a better understanding of genetic variations that affect Arc, or its binding partners, might help to pave the way to more efficient treatments and prevention strategies in keeping with the promises of precision medicine. In particular, individual variability in Arc genetics could provide valuable tools to better address abnormalities in cognitive and social processes.</p>
</sec>
<sec id="s14">
<title>Author Contributions</title>
<p>FP and FM found the materials and wrote the article.</p>
</sec>
<sec id="s15">
<title>Conflict of Interest Statement</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
</body>
<back>
<ack>
<p>We thank Dr. H. Huang for English editing. FM and FP were supported by the Istituto Italiano di Tecnologia, the 2015 NARSAD Independent Investigator Grant 23234, and by the Compagnia di San Paolo grant 2015-0321.</p>
</ack>
<ref-list>
<title>References</title>
<ref id="B1">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alberi</surname><given-names>L.</given-names></name><name><surname>Liu</surname><given-names>S.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Badie</surname><given-names>R.</given-names></name><name><surname>Smith-Hicks</surname><given-names>C.</given-names></name><name><surname>Wu</surname><given-names>J.</given-names></name><etal></etal></person-group>. (<year>2011</year>). <article-title>Activity-induced Notch signaling in neurons requires Arc/Arg3.1 and is essential for synaptic plasticity in hippocampal networks</article-title>. <source/>Neuron
<volume>69</volume>, <fpage>437</fpage>–<lpage>444</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuron.2011.01.004</pub-id><pub-id pub-id-type="pmid">21315255</pub-id></mixed-citation>
</ref>
<ref id="B2">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aleman</surname><given-names>A.</given-names></name><name><surname>Hijman</surname><given-names>R.</given-names></name><name><surname>de Haan</surname><given-names>E. H.</given-names></name><name><surname>Kahn</surname><given-names>R. S.</given-names></name></person-group> (<year>1999</year>). <article-title>Memory impairment in schizophrenia: a meta-analysis</article-title>. <source/>Am. J. Psychiatry
<volume>156</volume>, <fpage>1358</fpage>–<lpage>1366</lpage>. <pub-id pub-id-type="doi">10.1176/ajp.156.9.1358</pub-id><pub-id pub-id-type="pmid">10484945</pub-id></mixed-citation>
</ref>
<ref id="B3">
<mixed-citation publication-type="book"><person-group person-group-type="author"><collab>American Psychiatric Association</collab></person-group> (<year>2013</year>). <source/>Diagnostic and Statistical Manual of Mental Disorders.
<publisher-loc>Washington, DC</publisher-loc>: <publisher-name>American Psychiatric Association</publisher-name>.</mixed-citation>
</ref>
<ref id="B4">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Andiné</surname><given-names>P.</given-names></name><name><surname>Widermark</surname><given-names>N.</given-names></name><name><surname>Axelsson</surname><given-names>R.</given-names></name><name><surname>Nyberg</surname><given-names>G.</given-names></name><name><surname>Olofsson</surname><given-names>U.</given-names></name><name><surname>Mårtensson</surname><given-names>E.</given-names></name><etal></etal></person-group>. (<year>1999</year>). <article-title>Characterization of MK-801-induced behavior as a putative rat model of psychosis</article-title>. <source/>J. Pharmacol. Exp. Ther.
<volume>290</volume>, <fpage>1393</fpage>–<lpage>1408</lpage>. <pub-id pub-id-type="pmid">10454519</pub-id></mixed-citation>
</ref>
<ref id="B5">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arguello</surname><given-names>P. A.</given-names></name><name><surname>Gogos</surname><given-names>J. A.</given-names></name></person-group> (<year>2006</year>). <article-title>Modeling madness in mice: one piece at a time</article-title>. <source/>Neuron
<volume>52</volume>, <fpage>179</fpage>–<lpage>196</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuron.2006.09.023</pub-id><pub-id pub-id-type="pmid">17015235</pub-id></mixed-citation>
</ref>
<ref id="B6">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Banerjee</surname><given-names>P. S.</given-names></name><name><surname>Aston</surname><given-names>J.</given-names></name><name><surname>Khundakar</surname><given-names>A. A.</given-names></name><name><surname>Zetterstrom</surname><given-names>T. S.</given-names></name></person-group> (<year>2009</year>). <article-title>Differential regulation of psychostimulant-induced gene expression of brain derived neurotrophic factor and the immediate-early gene Arc in the juvenile and adult brain</article-title>. <source/>Eur. J. Neurosci.
<volume>29</volume>, <fpage>465</fpage>–<lpage>476</lpage>. <pub-id pub-id-type="doi">10.1111/j.1460-9568.2008.06601.x</pub-id><pub-id pub-id-type="pmid">19222557</pub-id></mixed-citation>
</ref>
<ref id="B7">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barker</surname><given-names>G. R. I.</given-names></name><name><surname>Bird</surname><given-names>F.</given-names></name><name><surname>Alexander</surname><given-names>V.</given-names></name><name><surname>Warburton</surname><given-names>E. C.</given-names></name></person-group> (<year>2007</year>). <article-title>Recognition memory for objects, place, and temporal order: a disconnection analysis of the role of the medial prefrontal cortex and perirhinal cortex</article-title>. <source/>J. Neurosci.
<volume>27</volume>, <fpage>2948</fpage>–<lpage>2957</lpage>. <pub-id pub-id-type="doi">10.1523/jneurosci.5289-06.2007</pub-id><pub-id pub-id-type="pmid">17360918</pub-id></mixed-citation>
</ref>
<ref id="B8">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beckstead</surname><given-names>R. M.</given-names></name><name><surname>Domesick</surname><given-names>V. B.</given-names></name><name><surname>Nauta</surname><given-names>W. J.</given-names></name></person-group> (<year>1979</year>). <article-title>Efferent connections of the substantia nigra and ventral tegmental area in the rat</article-title>. <source/>Brain Res.
<volume>175</volume>, <fpage>191</fpage>–<lpage>217</lpage>. <pub-id pub-id-type="doi">10.1016/0006-8993(79)91001-1</pub-id><pub-id pub-id-type="pmid">314832</pub-id></mixed-citation>
</ref>
<ref id="B9">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bi</surname><given-names>R.</given-names></name><name><surname>Kong</surname><given-names>L. L.</given-names></name><name><surname>Xu</surname><given-names>M.</given-names></name><name><surname>Li</surname><given-names>G. D.</given-names></name><name><surname>Zhang</surname><given-names>D. F.</given-names></name><collab>Alzheimer’s Disease Neuroimaging Initiative</collab><etal></etal></person-group>. (<year>2017</year>). <article-title>The arc gene confers genetic susceptibility to Alzheimer’s disease in Han Chinese</article-title>. <source/>Mol. Neurobiol. [Epub ahead of print]. <pub-id pub-id-type="doi">10.1007/s12035-017-0397-6</pub-id><pub-id pub-id-type="pmid">28108859</pub-id></mixed-citation>
</ref>
<ref id="B10">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Biever</surname><given-names>A.</given-names></name><name><surname>Boubaker-Vitre</surname><given-names>J.</given-names></name><name><surname>Cutando</surname><given-names>L.</given-names></name><name><surname>Gracia-Rubio</surname><given-names>I.</given-names></name><name><surname>Costa-Mattioli</surname><given-names>M.</given-names></name><name><surname>Puighermanal</surname><given-names>E.</given-names></name><etal></etal></person-group>. (<year>2017</year>). <article-title>Repeated exposure to D-Amphetamine decreases global protein synthesis and regulates the translation of a subset of mRNAs in the striatum</article-title>. <source/>Front. Mol. Neurosci.
<volume>9</volume>:<fpage>165</fpage>. <pub-id pub-id-type="doi">10.3389/fnmol.2016.00165</pub-id><pub-id pub-id-type="pmid">28119566</pub-id></mixed-citation>
</ref>
<ref id="B11">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Billeke</surname><given-names>P.</given-names></name><name><surname>Aboitiz</surname><given-names>F.</given-names></name></person-group> (<year>2013</year>). <article-title>Social cognition in schizophrenia: from social stimuli processing to social engagement</article-title>. <source/>Front. Psychiatry
<volume>4</volume>:<fpage>4</fpage>. <pub-id pub-id-type="doi">10.3389/fpsyt.2013.00004</pub-id><pub-id pub-id-type="pmid">23444313</pub-id></mixed-citation>
</ref>
<ref id="B12">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bloomer</surname><given-names>W. A.</given-names></name><name><surname>VanDongen</surname><given-names>H. M.</given-names></name><name><surname>VanDongen</surname><given-names>A. M.</given-names></name></person-group> (<year>2008</year>). <article-title>Arc/Arg3.1 translation is controlled by convergent <italic>N</italic>-methyl-<italic>D</italic>-aspartate and G<sub>s</sub>-coupled receptor signaling pathways</article-title>. <source/>J. Biol. Chem.
<volume>283</volume>, <fpage>582</fpage>–<lpage>592</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.m702451200</pub-id><pub-id pub-id-type="pmid">17981809</pub-id></mixed-citation>
</ref>
<ref id="B13">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bourgeron</surname><given-names>T.</given-names></name></person-group> (<year>2015</year>). <article-title>From the genetic architecture to synaptic plasticity in autism spectrum disorder</article-title>. <source/>Nat. Rev. Neurosci.
<volume>16</volume>, <fpage>551</fpage>–<lpage>563</lpage>. <pub-id pub-id-type="doi">10.1038/nrn3992</pub-id><pub-id pub-id-type="pmid">26289574</pub-id></mixed-citation>
</ref>
<ref id="B14">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Braff</surname><given-names>D. L.</given-names></name><name><surname>Geyer</surname><given-names>M. A.</given-names></name></person-group> (<year>1990</year>). <article-title>Sensorimotor gating and schizophrenia. Human and animal model studies</article-title>. <source/>Arch. Gen. Psychiatry
<volume>47</volume>, <fpage>181</fpage>–<lpage>188</lpage>. <pub-id pub-id-type="doi">10.1001/archpsyc.1990.01810140081011</pub-id><pub-id pub-id-type="pmid">2405807</pub-id></mixed-citation>
</ref>
<ref id="B15">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bramham</surname><given-names>C. R.</given-names></name><name><surname>Alme</surname><given-names>M. N.</given-names></name><name><surname>Bittins</surname><given-names>M.</given-names></name><name><surname>Kuipers</surname><given-names>S. D.</given-names></name><name><surname>Nair</surname><given-names>R. R.</given-names></name><name><surname>Pai</surname><given-names>B.</given-names></name><etal></etal></person-group>. (<year>2010</year>). <article-title>The arc of synaptic memory</article-title>. <source/>Exp. Brain Res.
<volume>200</volume>, <fpage>125</fpage>–<lpage>140</lpage>. <pub-id pub-id-type="doi">10.1007/s00221-009-1959-2</pub-id><pub-id pub-id-type="pmid">19690847</pub-id></mixed-citation>
</ref>
<ref id="B16">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bugarski-Kirola</surname><given-names>D.</given-names></name><name><surname>Iwata</surname><given-names>N.</given-names></name><name><surname>Sameljak</surname><given-names>S.</given-names></name><name><surname>Reid</surname><given-names>C.</given-names></name><name><surname>Blaettler</surname><given-names>T.</given-names></name><name><surname>Millar</surname><given-names>L.</given-names></name><etal></etal></person-group>. (<year>2016</year>). <article-title>Efficacy and safety of adjunctive bitopertin versus placebo in patients with suboptimally controlled symptoms of schizophrenia treated with antipsychotics: results from three phase 3, randomised, double-blind, parallel-group, placebo-controlled, multicentre studies in the SearchLyte clinical trial programme</article-title>. <source/>Lancet Psychiatry
<volume>3</volume>, <fpage>1115</fpage>–<lpage>1128</lpage>. <pub-id pub-id-type="doi">10.1016/s2215-0366(16)30344-3</pub-id><pub-id pub-id-type="pmid">27816567</pub-id></mixed-citation>
</ref>
<ref id="B17">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cadenhead</surname><given-names>K. S.</given-names></name><name><surname>Geyer</surname><given-names>M. A.</given-names></name><name><surname>Braff</surname><given-names>D. L.</given-names></name></person-group> (<year>1993</year>). <article-title>Impaired startle prepulse inhibition and habituation in patients with schizotypal personality disorder</article-title>. <source/>Am. J. Psychiatry
<volume>150</volume>, <fpage>1862</fpage>–<lpage>1867</lpage>. <pub-id pub-id-type="doi">10.1176/ajp.150.12.1862</pub-id><pub-id pub-id-type="pmid">8238643</pub-id></mixed-citation>
</ref>
<ref id="B18">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cadenhead</surname><given-names>K. S.</given-names></name><name><surname>Swerdlow</surname><given-names>N. R.</given-names></name><name><surname>Shafer</surname><given-names>K. M.</given-names></name><name><surname>Diaz</surname><given-names>M.</given-names></name><name><surname>Braff</surname><given-names>D. L.</given-names></name></person-group> (<year>2000</year>). <article-title>Modulation of the startle response and startle laterality in relatives of schizophrenic patients and in subjects with schizotypal personality disorder: evidence of inhibitory deficits</article-title>. <source/>Am. J. Psychiatry
<volume>157</volume>, <fpage>1660</fpage>–<lpage>1668</lpage>. <pub-id pub-id-type="doi">10.1176/appi.ajp.157.10.1660</pub-id><pub-id pub-id-type="pmid">11007721</pub-id></mixed-citation>
</ref>
<ref id="B19">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cao</surname><given-names>C.</given-names></name><name><surname>Rioult-Pedotti</surname><given-names>M. S.</given-names></name><name><surname>Migani</surname><given-names>P.</given-names></name><name><surname>Yu</surname><given-names>C. J.</given-names></name><name><surname>Tiwari</surname><given-names>R.</given-names></name><name><surname>Parang</surname><given-names>K.</given-names></name><etal></etal></person-group>. (<year>2013</year>). <article-title>Impairment of TrkB-PSD-95 signaling in Angelman syndrome</article-title>. <source/>PLoS Biol.
<volume>11</volume>:<fpage>e1001478</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pbio.1001478</pub-id><pub-id pub-id-type="pmid">23424281</pub-id></mixed-citation>
</ref>
<ref id="B20">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cardno</surname><given-names>A. G.</given-names></name><name><surname>Gottesman</surname><given-names>I. I.</given-names></name></person-group> (<year>2000</year>). <article-title>Twin studies of schizophrenia: from bow-and-arrow concordances to star wars Mx and functional genomics</article-title>. <source/>Am. J. Med. Genet.
<volume>97</volume>, <fpage>12</fpage>–<lpage>17</lpage>. <pub-id pub-id-type="doi">10.1002/(sici)1096-8628(200021)97:1&lt;12::aid-ajmg3&gt;3.3.co;2-l</pub-id><pub-id pub-id-type="pmid">10813800</pub-id></mixed-citation>
</ref>
<ref id="B21">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>Y.</given-names></name><name><surname>Bang</surname><given-names>S.</given-names></name><name><surname>McMullen</surname><given-names>M. F.</given-names></name><name><surname>Kazi</surname><given-names>H.</given-names></name><name><surname>Talbot</surname><given-names>K.</given-names></name><name><surname>Ho</surname><given-names>M. X.</given-names></name><etal></etal></person-group>. (<year>2017</year>). <article-title>Neuronal activity-induced sterol regulatory element binding protein-1 (SREBP1) is disrupted in dysbindin-null mice-potential link to cognitive impairment in schizophrenia</article-title>. <source/>Mol. Neurobiol.
<volume>54</volume>, <fpage>1699</fpage>–<lpage>1709</lpage>. <pub-id pub-id-type="doi">10.1007/s12035-016-9773-x</pub-id><pub-id pub-id-type="pmid">26873854</pub-id></mixed-citation>
</ref>
<ref id="B22">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chia</surname><given-names>C.</given-names></name><name><surname>Otto</surname><given-names>T.</given-names></name></person-group> (<year>2013</year>). <article-title>Hippocampal Arc (Arg3.1) expression is induced by memory recall and required for memory reconsolidation in trace fear conditioning</article-title>. <source/>Neurobiol. Learn. Mem.
<volume>106</volume>, <fpage>48</fpage>–<lpage>55</lpage>. <pub-id pub-id-type="doi">10.1016/j.nlm.2013.06.021</pub-id><pub-id pub-id-type="pmid">23872190</pub-id></mixed-citation>
</ref>
<ref id="B23">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chowdhury</surname><given-names>S.</given-names></name><name><surname>Shepherd</surname><given-names>J. D.</given-names></name><name><surname>Okuno</surname><given-names>H.</given-names></name><name><surname>Lyford</surname><given-names>G.</given-names></name><name><surname>Petralia</surname><given-names>R. S.</given-names></name><name><surname>Plath</surname><given-names>N.</given-names></name><etal></etal></person-group>. (<year>2006</year>). <article-title>Arc/Arg3.1 interacts with the endocytic machinery to regulate AMPA receptor trafficking</article-title>. <source/>Neuron
<volume>52</volume>, <fpage>445</fpage>–<lpage>459</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuron.2006.08.033</pub-id><pub-id pub-id-type="pmid">17088211</pub-id></mixed-citation>
</ref>
<ref id="B25">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Contarino</surname><given-names>A.</given-names></name><name><surname>Kitchener</surname><given-names>P.</given-names></name><name><surname>Vallée</surname><given-names>M.</given-names></name><name><surname>Papaleo</surname><given-names>F.</given-names></name><name><surname>Piazza</surname><given-names>P. V.</given-names></name></person-group> (<year>2017</year>). <article-title>CRF1 receptor-deficiency increases cocaine reward</article-title>. <source/>Neuropharmacology
<volume>117</volume>, <fpage>41</fpage>–<lpage>48</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuropharm.2017.01.024</pub-id><pub-id pub-id-type="pmid">28137450</pub-id></mixed-citation>
</ref>
<ref id="B26">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Coyle</surname><given-names>J. T.</given-names></name></person-group> (<year>2006</year>). <article-title>Glutamate and schizophrenia: beyond the dopamine hypothesis</article-title>. <source/>Cell. Mol. Neurobiol.
<volume>26</volume>, <fpage>363</fpage>–<lpage>382</lpage>. <pub-id pub-id-type="doi">10.1007/s10571-006-9062-8</pub-id><pub-id pub-id-type="pmid">16773445</pub-id></mixed-citation>
</ref>
<ref id="B27">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Czerniawski</surname><given-names>J.</given-names></name><name><surname>Ree</surname><given-names>F.</given-names></name><name><surname>Chia</surname><given-names>C.</given-names></name><name><surname>Ramamoorthi</surname><given-names>K.</given-names></name><name><surname>Kumata</surname><given-names>Y.</given-names></name><name><surname>Otto</surname><given-names>T. A.</given-names></name></person-group> (<year>2011</year>). <article-title>The importance of having Arc: expression of the immediate-early gene Arc is required for hippocampus-dependent fear conditioning and blocked by NMDA receptor antagonism</article-title>. <source/>J. Neurosci.
<volume>31</volume>, <fpage>11200</fpage>–<lpage>11207</lpage>. <pub-id pub-id-type="doi">10.1523/jneurosci.2211-11.2011</pub-id><pub-id pub-id-type="pmid">21813681</pub-id></mixed-citation>
</ref>
<ref id="B28">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dreher</surname><given-names>J.-C.</given-names></name><name><surname>Banquet</surname><given-names>J.-P.</given-names></name><name><surname>Allilaire</surname><given-names>J. F.</given-names></name><name><surname>Paillère-Martinot</surname><given-names>M.-L.</given-names></name><name><surname>Dubois</surname><given-names>B.</given-names></name><name><surname>Burnod</surname><given-names>Y.</given-names></name></person-group> (<year>2001</year>). <article-title>Temporal order and spatial memory in schizophrenia: a parametric study</article-title>. <source/>Schizophr. Res.
<volume>51</volume>, <fpage>137</fpage>–<lpage>147</lpage>. <pub-id pub-id-type="doi">10.1016/s0920-9964(00)00151-1</pub-id><pub-id pub-id-type="pmid">11518634</pub-id></mixed-citation>
</ref>
<ref id="B29">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ebert</surname><given-names>D. H.</given-names></name><name><surname>Greenberg</surname><given-names>M. E.</given-names></name></person-group> (<year>2013</year>). <article-title>Activity-dependent neuronal signalling and autism spectrum disorder</article-title>. <source/>Nature
<volume>493</volume>, <fpage>327</fpage>–<lpage>337</lpage>. <pub-id pub-id-type="doi">10.1038/nature11860</pub-id><pub-id pub-id-type="pmid">23325215</pub-id></mixed-citation>
</ref>
<ref id="B30">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fett</surname><given-names>A. K.</given-names></name><name><surname>Viechtbauer</surname><given-names>W.</given-names></name><name><surname>Dominguez</surname><given-names>M. D.</given-names></name><name><surname>Penn</surname><given-names>D. L.</given-names></name><name><surname>van Os</surname><given-names>J.</given-names></name><name><surname>Krabbendam</surname><given-names>L.</given-names></name></person-group> (<year>2011</year>). <article-title>The relationship between neurocognition and social cognition with functional outcomes in schizophrenia: a meta-analysis</article-title>. <source/>Neurosci. Biobehav. Rev.
<volume>35</volume>, <fpage>573</fpage>–<lpage>588</lpage>. <pub-id pub-id-type="doi">10.1016/j.neubiorev.2010.07.001</pub-id><pub-id pub-id-type="pmid">20620163</pub-id></mixed-citation>
</ref>
<ref id="B31">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Folley</surname><given-names>B. S.</given-names></name><name><surname>Astur</surname><given-names>R.</given-names></name><name><surname>Jagannathan</surname><given-names>K.</given-names></name><name><surname>Calhoun</surname><given-names>V. D.</given-names></name><name><surname>Pearlson</surname><given-names>G. D.</given-names></name></person-group> (<year>2010</year>). <article-title>Anomalous neural circuit function in schizophrenia during a virtual Morris water task</article-title>. <source/>Neuroimage
<volume>49</volume>, <fpage>3373</fpage>–<lpage>3384</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuroimage.2009.11.034</pub-id><pub-id pub-id-type="pmid">19948225</pub-id></mixed-citation>
</ref>
<ref id="B32">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Frohlich</surname><given-names>J.</given-names></name><name><surname>Van Horn</surname><given-names>J. D.</given-names></name></person-group> (<year>2014</year>). <article-title>Reviewing the ketamine model for schizophrenia</article-title>. <source/>J. Psychopharmacol.
<volume>28</volume>, <fpage>287</fpage>–<lpage>302</lpage>. <pub-id pub-id-type="doi">10.1177/0269881113512909</pub-id><pub-id pub-id-type="pmid">24257811</pub-id></mixed-citation>
</ref>
<ref id="B33">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fromer</surname><given-names>M.</given-names></name><name><surname>Pocklington</surname><given-names>A. J.</given-names></name><name><surname>Kavanagh</surname><given-names>D. H.</given-names></name><name><surname>Williams</surname><given-names>H. J.</given-names></name><name><surname>Dwyer</surname><given-names>S.</given-names></name><name><surname>Gormley</surname><given-names>P.</given-names></name><etal></etal></person-group>. (<year>2014</year>). <article-title><italic>De novo</italic> mutations in schizophrenia implicate synaptic networks</article-title>. <source/>Nature
<volume>506</volume>, <fpage>179</fpage>–<lpage>184</lpage>. <pub-id pub-id-type="doi">10.1038/nature12929</pub-id><pub-id pub-id-type="pmid">24463507</pub-id></mixed-citation>
</ref>
<ref id="B34">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fumagalli</surname><given-names>F.</given-names></name><name><surname>Franchi</surname><given-names>C.</given-names></name><name><surname>Caffino</surname><given-names>L.</given-names></name><name><surname>Racagni</surname><given-names>G.</given-names></name><name><surname>Riva</surname><given-names>M. A.</given-names></name><name><surname>Cervo</surname><given-names>L.</given-names></name></person-group> (<year>2009</year>). <article-title>Single session of cocaine intravenous self-administration shapes goal-oriented behaviours and up-regulates Arc mRNA levels in rat medial prefrontal cortex</article-title>. <source/>Int. J. Neuropsychopharmacol.
<volume>12</volume>, <fpage>423</fpage>–<lpage>429</lpage>. <pub-id pub-id-type="doi">10.1017/s1461145708009681</pub-id><pub-id pub-id-type="pmid">19025723</pub-id></mixed-citation>
</ref>
<ref id="B35">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gao</surname><given-names>M.</given-names></name><name><surname>Sossa</surname><given-names>K.</given-names></name><name><surname>Song</surname><given-names>L.</given-names></name><name><surname>Errington</surname><given-names>L.</given-names></name><name><surname>Cummings</surname><given-names>L.</given-names></name><name><surname>Hwang</surname><given-names>H.</given-names></name><etal></etal></person-group>. (<year>2010</year>). <article-title>A specific requirement of Arc/Arg3.1 for visual experience-induced homeostatic synaptic plasticity in mouse primary visual cortex</article-title>. <source/>J. Neurosci.
<volume>30</volume>, <fpage>7168</fpage>–<lpage>7178</lpage>. <pub-id pub-id-type="doi">10.1523/jneurosci.1067-10.2010</pub-id><pub-id pub-id-type="pmid">20505084</pub-id></mixed-citation>
</ref>
<ref id="B36">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garber</surname><given-names>K. B.</given-names></name><name><surname>Visootsak</surname><given-names>J.</given-names></name><name><surname>Warren</surname><given-names>S. T.</given-names></name></person-group> (<year>2008</year>). <article-title>Fragile X syndrome</article-title>. <source/>Eur. J. Hum. Genet.
<volume>16</volume>, <fpage>666</fpage>–<lpage>672</lpage>. <pub-id pub-id-type="doi">10.1038/ejhg.2008.61</pub-id><pub-id pub-id-type="pmid">18398441</pub-id></mixed-citation>
</ref>
<ref id="B37">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gard</surname><given-names>D. E.</given-names></name><name><surname>Fisher</surname><given-names>M.</given-names></name><name><surname>Garrett</surname><given-names>C.</given-names></name><name><surname>Genevsky</surname><given-names>A.</given-names></name><name><surname>Vinogradov</surname><given-names>S.</given-names></name></person-group> (<year>2009</year>). <article-title>Motivation and its relationship to neurocognition, social cognition, and functional outcome in schizophrenia</article-title>. <source/>Schizophr. Res.
<volume>115</volume>, <fpage>74</fpage>–<lpage>81</lpage>. <pub-id pub-id-type="doi">10.1016/j.schres.2009.08.015</pub-id><pub-id pub-id-type="pmid">19783407</pub-id></mixed-citation>
</ref>
<ref id="B38">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goes</surname><given-names>F. S.</given-names></name><name><surname>Pirooznia</surname><given-names>M.</given-names></name><name><surname>Parla</surname><given-names>J. S.</given-names></name><name><surname>Kramer</surname><given-names>M.</given-names></name><name><surname>Ghiban</surname><given-names>E.</given-names></name><name><surname>Mavruk</surname><given-names>S.</given-names></name><etal></etal></person-group>. (<year>2016</year>). <article-title>Exome sequencing of familial bipolar disorder</article-title>. <source/>JAMA Psychiatry
<volume>73</volume>, <fpage>590</fpage>–<lpage>597</lpage>. <pub-id pub-id-type="doi">10.1001/jamapsychiatry.2016.0251</pub-id><pub-id pub-id-type="pmid">27120077</pub-id></mixed-citation>
</ref>
<ref id="B39">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goldberg</surname><given-names>T. E.</given-names></name><name><surname>Weinberger</surname><given-names>D. R.</given-names></name><name><surname>Pliskin</surname><given-names>N. H.</given-names></name><name><surname>Berman</surname><given-names>K. F.</given-names></name><name><surname>Podd</surname><given-names>M. H.</given-names></name></person-group> (<year>1989</year>). <article-title>Recall memory deficit in schizophrenia. A possible manifestation of prefrontal dysfunction</article-title>. <source/>Schizophr. Res.
<volume>2</volume>, <fpage>251</fpage>–<lpage>257</lpage>. <pub-id pub-id-type="doi">10.1016/0920-9964(89)90001-7</pub-id><pub-id pub-id-type="pmid">2487166</pub-id></mixed-citation>
</ref>
<ref id="B40">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Green</surname><given-names>M. F.</given-names></name></person-group> (<year>1996</year>). <article-title>What are the functional consequences of neurocognitive deficits in schizophrenia?</article-title>
<source/>Am. J. Psychiatry
<volume>153</volume>, <fpage>321</fpage>–<lpage>330</lpage>. <pub-id pub-id-type="doi">10.1176/ajp.153.3.321</pub-id><pub-id pub-id-type="pmid">8610818</pub-id></mixed-citation>
</ref>
<ref id="B42">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Green</surname><given-names>M. F.</given-names></name><name><surname>Horan</surname><given-names>W. P.</given-names></name><name><surname>Lee</surname><given-names>J.</given-names></name></person-group> (<year>2015</year>). <article-title>Social cognition in schizophrenia</article-title>. <source/>Nat. Rev. Neurosci.
<volume>16</volume>, <fpage>620</fpage>–<lpage>631</lpage>. <pub-id pub-id-type="doi">10.1038/nrn4005</pub-id><pub-id pub-id-type="pmid">26373471</pub-id></mixed-citation>
</ref>
<ref id="B41">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Green</surname><given-names>M. F.</given-names></name><name><surname>Nuechterlein</surname><given-names>K. H.</given-names></name></person-group> (<year>1999</year>). <article-title>Should schizophrenia be treated as a neurocognitive disorder?</article-title>
<source/>Schizophr. Bull.
<volume>25</volume>, <fpage>309</fpage>–<lpage>319</lpage>. <pub-id pub-id-type="doi">10.1093/oxfordjournals.schbul.a033380</pub-id><pub-id pub-id-type="pmid">10416733</pub-id></mixed-citation>
</ref>
<ref id="B43">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Greer</surname><given-names>P. L.</given-names></name><name><surname>Hanayama</surname><given-names>R.</given-names></name><name><surname>Bloodgood</surname><given-names>B. L.</given-names></name><name><surname>Mardinly</surname><given-names>A. R.</given-names></name><name><surname>Lipton</surname><given-names>D. M.</given-names></name><name><surname>Flavell</surname><given-names>S. W.</given-names></name><etal></etal></person-group>. (<year>2010</year>). <article-title>The angelman syndrome protein Ube3A regulates synapse development by ubiquitinating arc</article-title>. <source/>Cell
<volume>140</volume>, <fpage>704</fpage>–<lpage>716</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2010.01.026</pub-id><pub-id pub-id-type="pmid">20211139</pub-id></mixed-citation>
</ref>
<ref id="B44">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guillozet-Bongaarts</surname><given-names>A. L.</given-names></name><name><surname>Hyde</surname><given-names>T. M.</given-names></name><name><surname>Dalley</surname><given-names>R. A.</given-names></name><name><surname>Hawrylycz</surname><given-names>M. J.</given-names></name><name><surname>Henry</surname><given-names>A.</given-names></name><name><surname>Hof</surname><given-names>P. R.</given-names></name><etal></etal></person-group>. (<year>2014</year>). <article-title>Altered gene expression in the dorsolateral prefrontal cortex of individuals with schizophrenia</article-title>. <source/>Mol. Psychiatry
<volume>19</volume>, <fpage>478</fpage>–<lpage>485</lpage>. <pub-id pub-id-type="doi">10.1038/mp.2013.30</pub-id><pub-id pub-id-type="pmid">23528911</pub-id></mixed-citation>
</ref>
<ref id="B45">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guzowski</surname><given-names>J. F.</given-names></name><name><surname>Lyford</surname><given-names>G. L.</given-names></name><name><surname>Stevenson</surname><given-names>G. D.</given-names></name><name><surname>Houston</surname><given-names>F. P.</given-names></name><name><surname>McGaugh</surname><given-names>J. L.</given-names></name><name><surname>Worley</surname><given-names>P. F.</given-names></name><etal></etal></person-group>. (<year>2000</year>). <article-title>Inhibition of activity-dependent arc protein expression in the rat hippocampus impairs the maintenance of long-term potentiation and the consolidation of long-term memory</article-title>. <source/>J. Neurosci.
<volume>20</volume>, <fpage>3993</fpage>–<lpage>4001</lpage>. <pub-id pub-id-type="pmid">10818134</pub-id></mixed-citation>
</ref>
<ref id="B46">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Halberstadt</surname><given-names>A. L.</given-names></name></person-group> (<year>1995</year>). <article-title>The phencyclidine-glutamate model of schizophrenia</article-title>. <source/>Clin. Neuropharmacol.
<volume>18</volume>, <fpage>237</fpage>–<lpage>249</lpage>. <pub-id pub-id-type="doi">10.1097/00002826-199506000-00004</pub-id><pub-id pub-id-type="pmid">8635182</pub-id></mixed-citation>
</ref>
<ref id="B47">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harvey</surname><given-names>P. D.</given-names></name><name><surname>Koren</surname><given-names>D.</given-names></name><name><surname>Reichenberg</surname><given-names>A.</given-names></name><name><surname>Bowie</surname><given-names>C. R.</given-names></name></person-group> (<year>2006</year>). <article-title>Negative symptoms and cognitive deficits: what is the nature of their relationship?</article-title>
<source/>Schizophr. Bull.
<volume>32</volume>, <fpage>250</fpage>–<lpage>258</lpage>. <pub-id pub-id-type="doi">10.1093/schbul/sbj011</pub-id><pub-id pub-id-type="pmid">16221995</pub-id></mixed-citation>
</ref>
<ref id="B48">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hasan</surname><given-names>A.</given-names></name><name><surname>Falkai</surname><given-names>P.</given-names></name><name><surname>Wobrock</surname><given-names>T.</given-names></name><name><surname>Lieberman</surname><given-names>J.</given-names></name><name><surname>Glenthoj</surname><given-names>B.</given-names></name><name><surname>Gattaz</surname><given-names>W. F.</given-names></name><etal></etal></person-group>. (<year>2013</year>). <article-title>World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects</article-title>. <source/>World J. Biol. Psychiatry
<volume>14</volume>, <fpage>2</fpage>–<lpage>44</lpage>. <pub-id pub-id-type="doi">10.3109/15622975.2012.739708</pub-id><pub-id pub-id-type="pmid">23216388</pub-id></mixed-citation>
</ref>
<ref id="B49">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname><given-names>J.</given-names></name><name><surname>Sathanoori</surname><given-names>M.</given-names></name><name><surname>Kochmar</surname><given-names>S.</given-names></name><name><surname>Azage</surname><given-names>M.</given-names></name><name><surname>Mann</surname><given-names>S.</given-names></name><name><surname>Madan-Khetarpal</surname><given-names>S.</given-names></name><etal></etal></person-group>. (<year>2015</year>). <article-title>A novel maternally inherited 8q24.3 and a rare paternally inherited 14q23.3 CNVs in a family with neurodevelopmental disorders</article-title>. <source/>Am. J. Med. Genet. A
<volume>167A</volume>, <fpage>1921</fpage>–<lpage>1926</lpage>. <pub-id pub-id-type="doi">10.1002/ajmg.a.37110</pub-id><pub-id pub-id-type="pmid">25866352</pub-id></mixed-citation>
</ref>
<ref id="B50">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huentelman</surname><given-names>M. J.</given-names></name><name><surname>Muppana</surname><given-names>L.</given-names></name><name><surname>Corneveaux</surname><given-names>J. J.</given-names></name><name><surname>Dinu</surname><given-names>V.</given-names></name><name><surname>Pruzin</surname><given-names>J. J.</given-names></name><name><surname>Reiman</surname><given-names>R.</given-names></name><etal></etal></person-group>. (<year>2015</year>). <article-title>Association of SNPs in EGR3 and ARC with schizophrenia supports a biological pathway for schizophrenia risk</article-title>. <source/>PLoS One
<volume>10</volume>:<fpage>e0135076</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0135076</pub-id><pub-id pub-id-type="pmid">26474411</pub-id></mixed-citation>
</ref>
<ref id="B51">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Iwata</surname><given-names>Y.</given-names></name><name><surname>Nakajima</surname><given-names>S.</given-names></name><name><surname>Suzuki</surname><given-names>T.</given-names></name><name><surname>Keefe</surname><given-names>R. S.</given-names></name><name><surname>Plitman</surname><given-names>E.</given-names></name><name><surname>Chung</surname><given-names>J. K.</given-names></name><etal></etal></person-group>. (<year>2015</year>). <article-title>Effects of glutamate positive modulators on cognitive deficits in schizophrenia: a systematic review and meta-analysis of double-blind randomized controlled trials</article-title>. <source/>Mol. Psychiatry
<volume>20</volume>, <fpage>1151</fpage>–<lpage>1160</lpage>. <pub-id pub-id-type="doi">10.1038/mp.2015.68</pub-id><pub-id pub-id-type="pmid">26077694</pub-id></mixed-citation>
</ref>
<ref id="B52">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jakkamsetti</surname><given-names>V.</given-names></name><name><surname>Tsai</surname><given-names>N. P.</given-names></name><name><surname>Gross</surname><given-names>C.</given-names></name><name><surname>Molinaro</surname><given-names>G.</given-names></name><name><surname>Collins</surname><given-names>K. A.</given-names></name><name><surname>Nicoletti</surname><given-names>F.</given-names></name><etal></etal></person-group>. (<year>2013</year>). <article-title>Experience-induced Arc/Arg3.1 primes CA1 pyramidal neurons for metabotropic glutamate receptor-dependent long-term synaptic depression</article-title>. <source/>Neuron
<volume>80</volume>, <fpage>72</fpage>–<lpage>79</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuron.2013.07.020</pub-id><pub-id pub-id-type="pmid">24094104</pub-id></mixed-citation>
</ref>
<ref id="B53">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kalsbeek</surname><given-names>A.</given-names></name><name><surname>Voorn</surname><given-names>P.</given-names></name><name><surname>Buijs</surname><given-names>R. M.</given-names></name><name><surname>Pool</surname><given-names>C. W.</given-names></name><name><surname>Uylings</surname><given-names>H. B.</given-names></name></person-group> (<year>1988</year>). <article-title>Development of the dopaminergic innervation in the prefrontal cortex of the rat</article-title>. <source/>J. Comp. Neurol.
<volume>269</volume>, <fpage>58</fpage>–<lpage>72</lpage>. <pub-id pub-id-type="doi">10.1002/cne.902690105</pub-id><pub-id pub-id-type="pmid">3361004</pub-id></mixed-citation>
</ref>
<ref id="B54">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kantrowitz</surname><given-names>J. T.</given-names></name><name><surname>Javitt</surname><given-names>D. C.</given-names></name></person-group> (<year>2010</year>). <article-title>N-methyl-D-aspartate (NMDA) receptor dysfunction or dysregulation: the final common pathway on the road to schizophrenia?</article-title>. <source/>Brain Res. Bull.
<volume>83</volume>, <fpage>108</fpage>–<lpage>121</lpage>. <pub-id pub-id-type="doi">10.1016/j.brainresbull.2010.04.006</pub-id><pub-id pub-id-type="pmid">20417696</pub-id></mixed-citation>
</ref>
<ref id="B55">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kozorovitskiy</surname><given-names>Y.</given-names></name><name><surname>Saunders</surname><given-names>A.</given-names></name><name><surname>Johnson</surname><given-names>C. A.</given-names></name><name><surname>Lowell</surname><given-names>B. B.</given-names></name><name><surname>Sabatini</surname><given-names>B. L.</given-names></name></person-group> (<year>2012</year>). <article-title>Recurrent network activity drives striatal synaptogenesis</article-title>. <source/>Nature
<volume>485</volume>, <fpage>646</fpage>–<lpage>650</lpage>. <pub-id pub-id-type="doi">10.1038/nature11052</pub-id><pub-id pub-id-type="pmid">22660328</pub-id></mixed-citation>
</ref>
<ref id="B56">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kumar</surname><given-names>V.</given-names></name><name><surname>Fahey</surname><given-names>P. G.</given-names></name><name><surname>Jong</surname><given-names>Y. J.</given-names></name><name><surname>Ramanan</surname><given-names>N.</given-names></name><name><surname>O’Malley</surname><given-names>K. L.</given-names></name></person-group> (<year>2012</year>). <article-title>Activation of intracellular metabotropic glutamate receptor 5 in striatal neurons leads to up-regulation of genes associated with sustained synaptic transmission including Arc/Arg3.1 protein</article-title>. <source/>J. Biol. Chem.
<volume>287</volume>, <fpage>5412</fpage>–<lpage>5425</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M111.301366</pub-id><pub-id pub-id-type="pmid">22179607</pub-id></mixed-citation>
</ref>
<ref id="B57">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lambert</surname><given-names>J. C.</given-names></name><name><surname>Ibrahim-Verbaas</surname><given-names>C. A.</given-names></name><name><surname>Harold</surname><given-names>D.</given-names></name><name><surname>Naj</surname><given-names>A. C.</given-names></name><name><surname>Sims</surname><given-names>R.</given-names></name><name><surname>Bellenguez</surname><given-names>C.</given-names></name><etal></etal></person-group>. (<year>2013</year>). <article-title>Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer’s disease</article-title>. <source/>Nat. Genet.
<volume>45</volume>, <fpage>1452</fpage>–<lpage>1458</lpage>. <pub-id pub-id-type="doi">10.1038/ng.2802</pub-id><pub-id pub-id-type="pmid">24162737</pub-id></mixed-citation>
</ref>
<ref id="B58">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Laruelle</surname><given-names>M.</given-names></name><name><surname>Abi-Dargham</surname><given-names>A.</given-names></name><name><surname>Gil</surname><given-names>R.</given-names></name><name><surname>Kegeles</surname><given-names>L.</given-names></name><name><surname>Innis</surname><given-names>R.</given-names></name></person-group> (<year>1999</year>). <article-title>Increased dopamine transmission in schizophrenia: relationship to illness phases</article-title>. <source/>Biol. Psychiatry
<volume>46</volume>, <fpage>56</fpage>–<lpage>72</lpage>. <pub-id pub-id-type="doi">10.1016/s0006-3223(99)00067-0</pub-id><pub-id pub-id-type="pmid">10394474</pub-id></mixed-citation>
</ref>
<ref id="B60">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lewis</surname><given-names>D. A.</given-names></name><name><surname>Gonzalez-Burgos</surname><given-names>G.</given-names></name></person-group> (<year>2006</year>). <article-title>Pathophysiologically based treatment interventions in schizophrenia</article-title>. <source/>Nat. Med.
<volume>12</volume>, <fpage>1016</fpage>–<lpage>1022</lpage>. <pub-id pub-id-type="doi">10.1038/nm1478</pub-id><pub-id pub-id-type="pmid">16960576</pub-id></mixed-citation>
</ref>
<ref id="B61">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lewis</surname><given-names>D. A.</given-names></name><name><surname>Levitt</surname><given-names>P.</given-names></name></person-group> (<year>2002</year>). <article-title>Schizophrenia as a disorder of neurodevelopment</article-title>. <source/>Annu. Rev. Neurosci.
<volume>25</volume>, <fpage>409</fpage>–<lpage>432</lpage>. <pub-id pub-id-type="doi">10.1146/annurev.neuro.25.112701.142754</pub-id><pub-id pub-id-type="pmid">12052915</pub-id></mixed-citation>
</ref>
<ref id="B59">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lewis</surname><given-names>B. L.</given-names></name><name><surname>O’Donnell</surname><given-names>P.</given-names></name></person-group> (<year>2000</year>). <article-title>Ventral tegmental area afferents to the prefrontal cortex maintain membrane potential ‘up’ states in pyramidal neurons via D(1) dopamine receptors</article-title>. <source/>Cereb. Cortex
<volume>10</volume>, <fpage>1168</fpage>–<lpage>1175</lpage>. <pub-id pub-id-type="doi">10.1093/cercor/10.12.1168</pub-id><pub-id pub-id-type="pmid">11073866</pub-id></mixed-citation>
</ref>
<ref id="B62">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Y.</given-names></name><name><surname>Pehrson</surname><given-names>A. L.</given-names></name><name><surname>Waller</surname><given-names>J. A.</given-names></name><name><surname>Dale</surname><given-names>E.</given-names></name><name><surname>Sanchez</surname><given-names>C.</given-names></name><name><surname>Gulinello</surname><given-names>M.</given-names></name></person-group> (<year>2015</year>). <article-title>A critical evaluation of the activity-regulated cytoskeleton-associated protein (Arc/Arg3.1)’s putative role in regulating dendritic plasticity, cognitive processes, and mood in animal models of depression</article-title>. <source/>Front. Neurosci.
<volume>9</volume>:<fpage>279</fpage>. <pub-id pub-id-type="doi">10.3389/fnins.2015.00279</pub-id><pub-id pub-id-type="pmid">26321903</pub-id></mixed-citation>
</ref>
<ref id="B63">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Link</surname><given-names>W.</given-names></name><name><surname>Konietzko</surname><given-names>U.</given-names></name><name><surname>Kauselmann</surname><given-names>G.</given-names></name><name><surname>Krug</surname><given-names>M.</given-names></name><name><surname>Schwanke</surname><given-names>B.</given-names></name><name><surname>Frey</surname><given-names>U.</given-names></name><etal></etal></person-group>. (<year>1995</year>). <article-title>Somatodendritic expression of an immediate early gene is regulated by synaptic activity</article-title>. <source/>Proc. Natl. Acad. Sci. U S A
<volume>92</volume>, <fpage>5734</fpage>–<lpage>5738</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.92.12.5734</pub-id><pub-id pub-id-type="pmid">7777577</pub-id></mixed-citation>
</ref>
<ref id="B64">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lyford</surname><given-names>G. L.</given-names></name><name><surname>Yamagata</surname><given-names>K.</given-names></name><name><surname>Kaufmann</surname><given-names>W. E.</given-names></name><name><surname>Barnes</surname><given-names>C. A.</given-names></name><name><surname>Sanders</surname><given-names>L. K.</given-names></name><name><surname>Copeland</surname><given-names>N. G.</given-names></name><etal></etal></person-group>. (<year>1995</year>). <article-title>Arc, a growth factor and activity-regulated gene, encodes a novel cytoskeleton-associated protein that is enriched in neuronal dendrites</article-title>. <source/>Neuron
<volume>14</volume>, <fpage>433</fpage>–<lpage>445</lpage>. <pub-id pub-id-type="doi">10.1016/0896-6273(95)90299-6</pub-id><pub-id pub-id-type="pmid">7857651</pub-id></mixed-citation>
</ref>
<ref id="B65">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Malkki</surname><given-names>H. A.</given-names></name><name><surname>Mertens</surname><given-names>P. E.</given-names></name><name><surname>Lankelma</surname><given-names>J. V.</given-names></name><name><surname>Vinck</surname><given-names>M.</given-names></name><name><surname>van Schalkwijk</surname><given-names>F. J.</given-names></name><name><surname>van Mourik-Donga</surname><given-names>L. B.</given-names></name><etal></etal></person-group>. (<year>2016</year>). <article-title>Effects of Arc/Arg3.1 gene deletion on rhythmic synchronization of hippocampal CA1 neurons during locomotor activity and sleep</article-title>. <source/>Neurobiol. Learn. Mem.
<volume>131</volume>, <fpage>155</fpage>–<lpage>165</lpage>. <pub-id pub-id-type="doi">10.1016/j.nlm.2016.03.021</pub-id><pub-id pub-id-type="pmid">27038743</pub-id></mixed-citation>
</ref>
<ref id="B66">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Managò</surname><given-names>F.</given-names></name><name><surname>Mereu</surname><given-names>M.</given-names></name><name><surname>Mastwal</surname><given-names>S.</given-names></name><name><surname>Mastrogiacomo</surname><given-names>R.</given-names></name><name><surname>Scheggia</surname><given-names>D.</given-names></name><name><surname>Emanuele</surname><given-names>M.</given-names></name><etal></etal></person-group>. (<year>2016</year>). <article-title>Genetic disruption of Arc/Arg3.1 in mice causes alterations in dopamine and neurobehavioral phenotypes related to schizophrenia</article-title>. <source/>Cell Rep.
<volume>16</volume>, <fpage>2116</fpage>–<lpage>2128</lpage>. <pub-id pub-id-type="doi">10.1016/j.celrep.2016.07.044</pub-id><pub-id pub-id-type="pmid">27524619</pub-id></mixed-citation>
</ref>
<ref id="B67">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Manitt</surname><given-names>C.</given-names></name><name><surname>Mimee</surname><given-names>A.</given-names></name><name><surname>Eng</surname><given-names>C.</given-names></name><name><surname>Pokinko</surname><given-names>M.</given-names></name><name><surname>Stroh</surname><given-names>T.</given-names></name><name><surname>Cooper</surname><given-names>H. M.</given-names></name><etal></etal></person-group>. (<year>2011</year>). <article-title>The netrin receptor DCC is required in the pubertal organization of mesocortical dopamine circuitry</article-title>. <source/>J. Neurosci.
<volume>31</volume>, <fpage>8381</fpage>–<lpage>8394</lpage>. <pub-id pub-id-type="doi">10.1523/JNEUROSCI.0606-11.2011</pub-id><pub-id pub-id-type="pmid">21653843</pub-id></mixed-citation>
</ref>
<ref id="B24">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marshall</surname><given-names>C. R.</given-names></name><name><surname>Howrigan</surname><given-names>D. P.</given-names></name><name><surname>Merico</surname><given-names>D.</given-names></name><name><surname>Thiruvahindrapuram</surname><given-names>B.</given-names></name><name><surname>Wu</surname><given-names>W.</given-names></name><name><surname>Greer</surname><given-names>D. S.</given-names></name></person-group> (<year>2017</year>). <article-title>Contribution of copy number variants to schizophrenia from a genome-wide study of 41,321 subjects</article-title>. <source/>Nat. Genet.
<volume>49</volume>, <fpage>27</fpage>–<lpage>35</lpage>. <pub-id pub-id-type="doi">10.1038/ng.3725</pub-id><pub-id pub-id-type="pmid">27869829</pub-id></mixed-citation>
</ref>
<ref id="B68">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mastwal</surname><given-names>S.</given-names></name><name><surname>Ye</surname><given-names>Y.</given-names></name><name><surname>Ren</surname><given-names>M.</given-names></name><name><surname>Jimenez</surname><given-names>D. V.</given-names></name><name><surname>Martinowich</surname><given-names>K.</given-names></name><name><surname>Gerfen</surname><given-names>C. R.</given-names></name><etal></etal></person-group>. (<year>2014</year>). <article-title>Phasic dopamine neuron activity elicits unique mesofrontal plasticity in adolescence</article-title>. <source/>J. Neurosci.
<volume>34</volume>, <fpage>9484</fpage>–<lpage>9496</lpage>. <pub-id pub-id-type="doi">10.1523/JNEUROSCI.1114-14.2014</pub-id><pub-id pub-id-type="pmid">25031392</pub-id></mixed-citation>
</ref>
<ref id="B69">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matsuo</surname><given-names>N.</given-names></name><name><surname>Yamasaki</surname><given-names>N.</given-names></name><name><surname>Ohira</surname><given-names>K.</given-names></name><name><surname>Takao</surname><given-names>K.</given-names></name><name><surname>Toyama</surname><given-names>K.</given-names></name><name><surname>Eguchi</surname><given-names>M.</given-names></name><etal></etal></person-group>. (<year>2009</year>). <article-title>Neural activity changes underlying the working memory deficit in α-CaMKII heterozygous knockout mice</article-title>. <source/>Front. Behav. Neurosci.
<volume>3</volume>:<fpage>20</fpage>. <pub-id pub-id-type="doi">10.3389/neuro.08.020.2009</pub-id><pub-id pub-id-type="pmid">19750198</pub-id></mixed-citation>
</ref>
<ref id="B70">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McCarthy</surname><given-names>S. E.</given-names></name><name><surname>Gillis</surname><given-names>J.</given-names></name><name><surname>Kramer</surname><given-names>M.</given-names></name><name><surname>Lihm</surname><given-names>J.</given-names></name><name><surname>Yoon</surname><given-names>S.</given-names></name><name><surname>Berstein</surname><given-names>Y.</given-names></name><etal></etal></person-group>. (<year>2014</year>). <article-title><italic>De novo</italic> mutations in schizophrenia implicate chromatin remodeling and support a genetic overlap with autism and intellectual disability</article-title>. <source/>Mol. Psychiatry
<volume>19</volume>, <fpage>652</fpage>–<lpage>658</lpage>. <pub-id pub-id-type="doi">10.1038/mp.2014.29</pub-id><pub-id pub-id-type="pmid">24776741</pub-id></mixed-citation>
</ref>
<ref id="B71">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McIntyre</surname><given-names>C. K.</given-names></name><name><surname>Miyashita</surname><given-names>T.</given-names></name><name><surname>Setlow</surname><given-names>B.</given-names></name><name><surname>Marjon</surname><given-names>K. D.</given-names></name><name><surname>Steward</surname><given-names>O.</given-names></name><name><surname>Guzowski</surname><given-names>J. F.</given-names></name><etal></etal></person-group>. (<year>2005</year>). <article-title>Memory-influencing intra-basolateral amygdala drug infusions modulate expression of Arc protein in the hippocampus</article-title>. <source/>Proc. Natl. Acad. Sci. U S A
<volume>102</volume>, <fpage>10718</fpage>–<lpage>10723</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.0504436102</pub-id><pub-id pub-id-type="pmid">16020527</pub-id></mixed-citation>
</ref>
<ref id="B72">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mereu</surname><given-names>M.</given-names></name><name><surname>Contarini</surname><given-names>G.</given-names></name><name><surname>Buonaguro</surname><given-names>E. F.</given-names></name><name><surname>Latte</surname><given-names>G.</given-names></name><name><surname>Managò</surname><given-names>F.</given-names></name><name><surname>Iasevoli</surname><given-names>F.</given-names></name><etal></etal></person-group>. (<year>2017</year>). <article-title>Dopamine transporter (DAT) genetic hypofunction in mice produces alterations consistent with ADHD but not schizophrenia or bipolar disorder</article-title>. <source/>Neuropharmacology
<volume>121</volume>, <fpage>179</fpage>–<lpage>194</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuropharm.2017.04.037</pub-id><pub-id pub-id-type="pmid">28454982</pub-id></mixed-citation>
</ref>
<ref id="B73">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Messaoudi</surname><given-names>E.</given-names></name><name><surname>Kanhema</surname><given-names>T.</given-names></name><name><surname>Soulé</surname><given-names>J.</given-names></name><name><surname>Tiron</surname><given-names>A.</given-names></name><name><surname>Dagyte</surname><given-names>G.</given-names></name><name><surname>da Silva</surname><given-names>B.</given-names></name><etal></etal></person-group>. (<year>2007</year>). <article-title>Sustained Arc/Arg3.1 synthesis controls long-term potentiation consolidation through regulation of local actin polymerization in the dentate gyrus <italic>in vivo</italic></article-title>. <source/>J. Neurosci.
<volume>27</volume>, <fpage>10445</fpage>–<lpage>10455</lpage>. <pub-id pub-id-type="doi">10.1523/JNEUROSCI.2883-07.2007</pub-id><pub-id pub-id-type="pmid">17898216</pub-id></mixed-citation>
</ref>
<ref id="B74">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meyer-Lindenberg</surname><given-names>A.</given-names></name><name><surname>Weinberger</surname><given-names>D. R.</given-names></name></person-group> (<year>2006</year>). <article-title>Intermediate phenotypes and genetic mechanisms of psychiatric disorders</article-title>. <source/>Nat. Rev. Neurosci.
<volume>7</volume>, <fpage>818</fpage>–<lpage>827</lpage>. <pub-id pub-id-type="doi">10.1038/nrn1993</pub-id><pub-id pub-id-type="pmid">16988657</pub-id></mixed-citation>
</ref>
<ref id="B75">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Millan</surname><given-names>M. J.</given-names></name><name><surname>Fone</surname><given-names>K.</given-names></name><name><surname>Steckler</surname><given-names>T.</given-names></name><name><surname>Horan</surname><given-names>W. P.</given-names></name></person-group> (<year>2014</year>). <article-title>Negative symptoms of schizophrenia: clinical characteristics, pathophysiological substrates, experimental models and prospects for improved treatment</article-title>. <source/>Eur. Neuropsychopharmacol.
<volume>24</volume>, <fpage>645</fpage>–<lpage>692</lpage>. <pub-id pub-id-type="doi">10.1016/j.euroneuro.2014.03.008</pub-id><pub-id pub-id-type="pmid">24820238</pub-id></mixed-citation>
</ref>
<ref id="B76">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miyamoto</surname><given-names>S.</given-names></name><name><surname>Duncan</surname><given-names>G. E.</given-names></name><name><surname>Marx</surname><given-names>C. E.</given-names></name><name><surname>Lieberman</surname><given-names>J. A.</given-names></name></person-group> (<year>2005</year>). <article-title>Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs</article-title>. <source/>Mol. Psychiatry
<volume>10</volume>, <fpage>79</fpage>–<lpage>104</lpage>. <pub-id pub-id-type="doi">10.1038/sj.mp.4001556</pub-id><pub-id pub-id-type="pmid">15289815</pub-id></mixed-citation>
</ref>
<ref id="B77">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miyashita</surname><given-names>T.</given-names></name><name><surname>Kubik</surname><given-names>S.</given-names></name><name><surname>Lewandowski</surname><given-names>G.</given-names></name><name><surname>Guzowski</surname><given-names>J. F.</given-names></name></person-group> (<year>2008</year>). <article-title>Networks of neurons, networks of genes: an integrated view of memory consolidation</article-title>. <source/>Neurobiol. Learn. Mem.
<volume>89</volume>, <fpage>269</fpage>–<lpage>284</lpage>. <pub-id pub-id-type="doi">10.1016/j.nlm.2007.08.012</pub-id><pub-id pub-id-type="pmid">17931913</pub-id></mixed-citation>
</ref>
<ref id="B78">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moro</surname><given-names>H.</given-names></name><name><surname>Sato</surname><given-names>H.</given-names></name><name><surname>Ida</surname><given-names>I.</given-names></name><name><surname>Oshima</surname><given-names>A.</given-names></name><name><surname>Sakurai</surname><given-names>N.</given-names></name><name><surname>Shihara</surname><given-names>N.</given-names></name><etal></etal></person-group>. (<year>2007</year>). <article-title>Effects of SKF-38393, a dopamine D1 receptor agonist on expression of amphetamine-induced behavioral sensitization and expression of immediate early gene arc in prefrontal cortex of rats</article-title>. <source/>Pharmacol. Biochem. Behav.
<volume>87</volume>, <fpage>56</fpage>–<lpage>64</lpage>. <pub-id pub-id-type="doi">10.1016/j.pbb.2007.03.020</pub-id><pub-id pub-id-type="pmid">17499349</pub-id></mixed-citation>
</ref>
<ref id="B79">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moy</surname><given-names>S. S.</given-names></name><name><surname>Nadler</surname><given-names>J. J.</given-names></name><name><surname>Perez</surname><given-names>A.</given-names></name><name><surname>Barbaro</surname><given-names>R. P.</given-names></name><name><surname>Johns</surname><given-names>J. M.</given-names></name><name><surname>Magnuson</surname><given-names>T. R.</given-names></name><etal></etal></person-group>. (<year>2004</year>). <article-title>Sociability and preference for social novelty in five inbred strains: an approach to assess autistic-like behavior in mice</article-title>. <source/>Genes Brain Behav.
<volume>3</volume>, <fpage>287</fpage>–<lpage>302</lpage>. <pub-id pub-id-type="doi">10.1111/j.1601-1848.2004.00076.x</pub-id><pub-id pub-id-type="pmid">15344922</pub-id></mixed-citation>
</ref>
<ref id="B80">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moy</surname><given-names>S. S.</given-names></name><name><surname>Nadler</surname><given-names>J. J.</given-names></name><name><surname>Young</surname><given-names>N. B.</given-names></name><name><surname>Nonneman</surname><given-names>R. J.</given-names></name><name><surname>Segall</surname><given-names>S. K.</given-names></name><name><surname>Andrade</surname><given-names>G. M.</given-names></name><etal></etal></person-group>. (<year>2008</year>). <article-title>Social approach and repetitive behavior in eleven inbred mouse strains</article-title>. <source/>Behav. Brain Res.
<volume>191</volume>, <fpage>118</fpage>–<lpage>129</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbr.2008.03.015</pub-id><pub-id pub-id-type="pmid">18440079</pub-id></mixed-citation>
</ref>
<ref id="B81">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mueser</surname><given-names>K. T.</given-names></name><name><surname>McGurk</surname><given-names>S. R.</given-names></name></person-group> (<year>2004</year>). <article-title>Schizophrenia</article-title>. <source/>Lancet
<volume>363</volume>, <fpage>2063</fpage>–<lpage>2072</lpage>. <pub-id pub-id-type="doi">10.1016/S0140-6736(04)16458-1</pub-id><pub-id pub-id-type="pmid">15207959</pub-id></mixed-citation>
</ref>
<ref id="B82">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Myrum</surname><given-names>C.</given-names></name><name><surname>Baumann</surname><given-names>A.</given-names></name><name><surname>Bustad</surname><given-names>H. J.</given-names></name><name><surname>Flydal</surname><given-names>M. I.</given-names></name><name><surname>Mariaule</surname><given-names>V.</given-names></name><name><surname>Alvira</surname><given-names>S.</given-names></name><etal></etal></person-group>. (<year>2015a</year>). <article-title>Arc is a flexible modular protein capable of reversible self-oligomerization</article-title>. <source/>Biochem. J.
<volume>468</volume>, <fpage>145</fpage>–<lpage>158</lpage>. <pub-id pub-id-type="doi">10.1042/BJ20141446</pub-id><pub-id pub-id-type="pmid">25748042</pub-id></mixed-citation>
</ref>
<ref id="B83">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Myrum</surname><given-names>C.</given-names></name><name><surname>Giddaluru</surname><given-names>S.</given-names></name><name><surname>Jacobsen</surname><given-names>K.</given-names></name><name><surname>Espeseth</surname><given-names>T.</given-names></name><name><surname>Nyberg</surname><given-names>L.</given-names></name><name><surname>Lundervold</surname><given-names>A. J.</given-names></name><etal></etal></person-group>. (<year>2015b</year>). <article-title>Common variants in the ARC gene are not associated with cognitive abilities</article-title>. <source/>Brain Behav.
<volume>5</volume>:<fpage>e00376</fpage>. <pub-id pub-id-type="doi">10.1002/brb3.376</pub-id><pub-id pub-id-type="pmid">26516611</pub-id></mixed-citation>
</ref>
<ref id="B84">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nakayama</surname><given-names>D.</given-names></name><name><surname>Iwata</surname><given-names>H.</given-names></name><name><surname>Teshirogi</surname><given-names>C.</given-names></name><name><surname>Ikegaya</surname><given-names>Y.</given-names></name><name><surname>Matsuki</surname><given-names>N.</given-names></name><name><surname>Nomura</surname><given-names>H.</given-names></name></person-group> (<year>2015</year>). <article-title>Long-delayed expression of the immediate early gene Arc/Arg3.1 refines neuronal circuits to perpetuate fear memory</article-title>. <source/>J. Neurosci.
<volume>35</volume>, <fpage>819</fpage>–<lpage>830</lpage>. <pub-id pub-id-type="doi">10.1523/JNEUROSCI.2525-14.2015</pub-id><pub-id pub-id-type="pmid">25589774</pub-id></mixed-citation>
</ref>
<ref id="B85">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Niere</surname><given-names>F.</given-names></name><name><surname>Wilkerson</surname><given-names>J. R.</given-names></name><name><surname>Huber</surname><given-names>K. M.</given-names></name></person-group> (<year>2012</year>). <article-title>Evidence for a fragile X mental retardation protein-mediated translational switch in metabotropic glutamate receptor-triggered Arc translation and long-term depression</article-title>. <source/>J. Neurosci.
<volume>32</volume>, <fpage>5924</fpage>–<lpage>5936</lpage>. <pub-id pub-id-type="doi">10.1523/JNEUROSCI.4650-11.2012</pub-id><pub-id pub-id-type="pmid">22539853</pub-id></mixed-citation>
</ref>
<ref id="B86">
<mixed-citation publication-type="webpage"><person-group person-group-type="author"><collab>NIH/NIMH</collab></person-group> (<year>2017</year>). <article-title>Research Domain Criteria (RDoC)</article-title>. Available online at: <ext-link ext-link-type="uri" xlink:href="https://www.nimh.nih.gov/research-priorities/rdoc/index.shtml">https://www.nimh.nih.gov/research-priorities/rdoc/index.shtml</ext-link></mixed-citation>
</ref>
<ref id="B87">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O’Donovan</surname><given-names>M. C.</given-names></name><name><surname>Owen</surname><given-names>M. J.</given-names></name></person-group> (<year>2016</year>). <article-title>The implications of the shared genetics of psychiatric disorders</article-title>. <source/>Nat. Med.
<volume>22</volume>, <fpage>1214</fpage>–<lpage>1219</lpage>. <pub-id pub-id-type="doi">10.1038/nm.4196</pub-id><pub-id pub-id-type="pmid">27783064</pub-id></mixed-citation>
</ref>
<ref id="B88">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Okuno</surname><given-names>H.</given-names></name><name><surname>Akashi</surname><given-names>K.</given-names></name><name><surname>Ishii</surname><given-names>Y.</given-names></name><name><surname>Yagishita-Kyo</surname><given-names>N.</given-names></name><name><surname>Suzuki</surname><given-names>K.</given-names></name><name><surname>Nonaka</surname><given-names>M.</given-names></name><etal></etal></person-group>. (<year>2012</year>). <article-title>Inverse synaptic tagging of inactive synapses via dynamic interaction of Arc/Arg3.1 with CaMKIIβ</article-title>. <source/>Cell
<volume>149</volume>, <fpage>886</fpage>–<lpage>898</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2012.02.062</pub-id><pub-id pub-id-type="pmid">22579289</pub-id></mixed-citation>
</ref>
<ref id="B89">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Papaleo</surname><given-names>F.</given-names></name><name><surname>Lipska</surname><given-names>B. K.</given-names></name><name><surname>Weinberger</surname><given-names>D. R.</given-names></name></person-group> (<year>2012</year>). <article-title>Mouse models of genetic effects on cognition: relevance to schizophrenia</article-title>. <source/>Neuropharmacology
<volume>62</volume>, <fpage>1204</fpage>–<lpage>1220</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuropharm.2011.04.025</pub-id><pub-id pub-id-type="pmid">21557953</pub-id></mixed-citation>
</ref>
<ref id="B90">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Park</surname><given-names>S.</given-names></name><name><surname>Park</surname><given-names>J. M.</given-names></name><name><surname>Kim</surname><given-names>S.</given-names></name><name><surname>Kim</surname><given-names>J. A.</given-names></name><name><surname>Shepherd</surname><given-names>J. D.</given-names></name><name><surname>Smith-Hicks</surname><given-names>C. L.</given-names></name><etal></etal></person-group>. (<year>2008</year>). <article-title>Elongation factor 2 and fragile X mental retardation protein control the dynamic translation of Arc/Arg3.1 essential for mGluR-LTD</article-title>. <source/>Neuron
<volume>59</volume>, <fpage>70</fpage>–<lpage>83</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuron.2008.05.023</pub-id><pub-id pub-id-type="pmid">18614030</pub-id></mixed-citation>
</ref>
<ref id="B91">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Plath</surname><given-names>N.</given-names></name><name><surname>Ohana</surname><given-names>O.</given-names></name><name><surname>Dammermann</surname><given-names>B.</given-names></name><name><surname>Errington</surname><given-names>M. L.</given-names></name><name><surname>Schmitz</surname><given-names>D.</given-names></name><name><surname>Gross</surname><given-names>C.</given-names></name><etal></etal></person-group>. (<year>2006</year>). <article-title>Arc/Arg3.1 is essential for the consolidation of synaptic plasticity and memories</article-title>. <source/>Neuron
<volume>52</volume>, <fpage>437</fpage>–<lpage>444</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuron.2006.08.024</pub-id><pub-id pub-id-type="pmid">17088210</pub-id></mixed-citation>
</ref>
<ref id="B92">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ploski</surname><given-names>J. E.</given-names></name><name><surname>Pierre</surname><given-names>V. J.</given-names></name><name><surname>Smucny</surname><given-names>J.</given-names></name><name><surname>Park</surname><given-names>K.</given-names></name><name><surname>Monsey</surname><given-names>M. S.</given-names></name><name><surname>Overeem</surname><given-names>K. A.</given-names></name><etal></etal></person-group>. (<year>2008</year>). <article-title>The activity-regulated cytoskeletal-associated protein (Arc/Arg3.1) is required for memory consolidation of pavlovian fear conditioning in the lateral amygdala</article-title>. <source/>J. Neurosci.
<volume>28</volume>, <fpage>12383</fpage>–<lpage>12395</lpage>. <pub-id pub-id-type="doi">10.1523/JNEUROSCI.1662-08.2008</pub-id><pub-id pub-id-type="pmid">19020031</pub-id></mixed-citation>
</ref>
<ref id="B93">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Purcell</surname><given-names>S. M.</given-names></name><name><surname>Moran</surname><given-names>J. L.</given-names></name><name><surname>Fromer</surname><given-names>M.</given-names></name><name><surname>Ruderfer</surname><given-names>D.</given-names></name><name><surname>Solovieff</surname><given-names>N.</given-names></name><name><surname>Roussos</surname><given-names>P.</given-names></name><etal></etal></person-group>. (<year>2014</year>). <article-title>A polygenic burden of rare disruptive mutations in schizophrenia</article-title>. <source/>Nature
<volume>506</volume>, <fpage>185</fpage>–<lpage>190</lpage>. <pub-id pub-id-type="doi">10.1038/nature12975</pub-id><pub-id pub-id-type="pmid">24463508</pub-id></mixed-citation>
</ref>
<ref id="B94">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ranganath</surname><given-names>C.</given-names></name><name><surname>Minzenberg</surname><given-names>M. J.</given-names></name><name><surname>Ragland</surname><given-names>J. D.</given-names></name></person-group> (<year>2008</year>). <article-title>The cognitive neuroscience of memory function and dysfunction in schizophrenia</article-title>. <source/>Biol. Psychiatry
<volume>64</volume>, <fpage>18</fpage>–<lpage>25</lpage>. <pub-id pub-id-type="doi">10.1016/j.biopsych.2008.04.011</pub-id><pub-id pub-id-type="pmid">18495087</pub-id></mixed-citation>
</ref>
<ref id="B95">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ren</surname><given-names>M.</given-names></name><name><surname>Cao</surname><given-names>V.</given-names></name><name><surname>Ye</surname><given-names>Y.</given-names></name><name><surname>Manji</surname><given-names>H. K.</given-names></name><name><surname>Wang</surname><given-names>K. H.</given-names></name></person-group> (<year>2014</year>). <article-title>Arc regulates experience-dependent persistent firing patterns in frontal cortex</article-title>. <source/>J. Neurosci.
<volume>34</volume>, <fpage>6583</fpage>–<lpage>6595</lpage>. <pub-id pub-id-type="doi">10.1523/JNEUROSCI.0167-14.2014</pub-id><pub-id pub-id-type="pmid">24806683</pub-id></mixed-citation>
</ref>
<ref id="B96">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rial Verde</surname><given-names>E. M.</given-names></name><name><surname>Lee-Osbourne</surname><given-names>J.</given-names></name><name><surname>Worley</surname><given-names>P. F.</given-names></name><name><surname>Malinow</surname><given-names>R.</given-names></name><name><surname>Cline</surname><given-names>H. T.</given-names></name></person-group> (<year>2006</year>). <article-title>Increased expression of the immediate-early gene arc/arg3.1 reduces AMPA receptor-mediated synaptic transmission</article-title>. <source/>Neuron
<volume>52</volume>, <fpage>461</fpage>–<lpage>474</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuron.2006.09.031</pub-id><pub-id pub-id-type="pmid">17088212</pub-id></mixed-citation>
</ref>
<ref id="B97">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rizzo</surname><given-names>L.</given-names></name><name><surname>Danion</surname><given-names>J. M.</given-names></name><name><surname>van der Linden</surname><given-names>M.</given-names></name><name><surname>Grange</surname><given-names>D.</given-names></name></person-group> (<year>1996</year>). <article-title>Patients with schizophrenia remember that an event has occurred, but not when</article-title>. <source/>Br. J. Psychiatry
<volume>168</volume>, <fpage>427</fpage>–<lpage>431</lpage>. <pub-id pub-id-type="doi">10.1192/bjp.168.4.427</pub-id><pub-id pub-id-type="pmid">8730938</pub-id></mixed-citation>
</ref>
<ref id="B98">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Salery</surname><given-names>M.</given-names></name><name><surname>Dos Santos</surname><given-names>M.</given-names></name><name><surname>Saint-Jour</surname><given-names>E.</given-names></name><name><surname>Moumné</surname><given-names>L.</given-names></name><name><surname>Pagès</surname><given-names>C.</given-names></name><name><surname>Kappès</surname><given-names>V.</given-names></name><etal></etal></person-group>. (<year>2017</year>). <article-title>Activity-regulated cytoskeleton-associated protein accumulates in the nucleus in response to cocaine and acts as a brake on chromatin remodeling and long-term behavioral alterations</article-title>. <source/>Biol. Psychiatry
<volume>81</volume>, <fpage>573</fpage>–<lpage>584</lpage>. <pub-id pub-id-type="doi">10.1016/j.biopsych.2016.05.025</pub-id><pub-id pub-id-type="pmid">27567310</pub-id></mixed-citation>
</ref>
<ref id="B99">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><collab>Schizophrenia Working Group of the Psychiatric Genomics Consortium</collab></person-group>. (<year>2014</year>). <article-title>Biological insights from 108 schizophrenia-associated genetic loci</article-title>. <source/>Nature
<volume>511</volume>, <fpage>421</fpage>–<lpage>427</lpage>. <pub-id pub-id-type="doi">10.1038/nature13595</pub-id><pub-id pub-id-type="pmid">25056061</pub-id></mixed-citation>
</ref>
<ref id="B100">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schwartz</surname><given-names>B. L.</given-names></name><name><surname>Deutsch</surname><given-names>L. H.</given-names></name><name><surname>Cohen</surname><given-names>C.</given-names></name><name><surname>Warden</surname><given-names>D.</given-names></name><name><surname>Deutsch</surname><given-names>S. I.</given-names></name></person-group> (<year>1991</year>). <article-title>Memory for temporal order in schizophrenia</article-title>. <source/>Biol. Psychiatry
<volume>29</volume>, <fpage>329</fpage>–<lpage>339</lpage>. <pub-id pub-id-type="doi">10.1016/0006-3223(91)90218-b</pub-id><pub-id pub-id-type="pmid">1674663</pub-id></mixed-citation>
</ref>
<ref id="B101">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shepherd</surname><given-names>J. D.</given-names></name><name><surname>Bear</surname><given-names>M. F.</given-names></name></person-group> (<year>2011</year>). <article-title>New views of Arc, a master regulator of synaptic plasticity</article-title>. <source/>Nat. Neurosci.
<volume>14</volume>, <fpage>279</fpage>–<lpage>284</lpage>. <pub-id pub-id-type="doi">10.1038/nn.2708</pub-id><pub-id pub-id-type="pmid">21278731</pub-id></mixed-citation>
</ref>
<ref id="B102">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shepherd</surname><given-names>J. D.</given-names></name><name><surname>Rumbaugh</surname><given-names>G.</given-names></name><name><surname>Wu</surname><given-names>J.</given-names></name><name><surname>Chowdhury</surname><given-names>S.</given-names></name><name><surname>Plath</surname><given-names>N.</given-names></name><name><surname>Kuhl</surname><given-names>D.</given-names></name><etal></etal></person-group>. (<year>2006</year>). <article-title>Arc/Arg3.1 mediates homeostatic synaptic scaling of AMPA receptors</article-title>. <source/>Neuron
<volume>52</volume>, <fpage>475</fpage>–<lpage>484</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuron.2006.08.034</pub-id><pub-id pub-id-type="pmid">17088213</pub-id></mixed-citation>
</ref>
<ref id="B103">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Simpson</surname><given-names>E. H.</given-names></name><name><surname>Kellendonk</surname><given-names>C.</given-names></name><name><surname>Kandel</surname><given-names>E.</given-names></name></person-group> (<year>2010</year>). <article-title>A possible role for the striatum in the pathogenesis of the cognitive symptoms of schizophrenia</article-title>. <source/>Neuron
<volume>65</volume>, <fpage>585</fpage>–<lpage>596</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuron.2010.02.014</pub-id><pub-id pub-id-type="pmid">20223196</pub-id></mixed-citation>
</ref>
<ref id="B104">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Slifstein</surname><given-names>M.</given-names></name><name><surname>van de Giessen</surname><given-names>E.</given-names></name><name><surname>Van Snellenberg</surname><given-names>J.</given-names></name><name><surname>Thompson</surname><given-names>J. L.</given-names></name><name><surname>Narendran</surname><given-names>R.</given-names></name><name><surname>Gil</surname><given-names>R.</given-names></name><etal></etal></person-group>. (<year>2015</year>). <article-title>Deficits in prefrontal cortical and extrastriatal dopamine release in schizophrenia: a positron emission tomographic functional magnetic resonance imaging study</article-title>. <source/>JAMA Psychiatry
<volume>72</volume>, <fpage>316</fpage>–<lpage>324</lpage>. <pub-id pub-id-type="doi">10.1001/jamapsychiatry.2014.2414</pub-id><pub-id pub-id-type="pmid">25651194</pub-id></mixed-citation>
</ref>
<ref id="B105">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname><given-names>S. E.</given-names></name><name><surname>Zhou</surname><given-names>Y. D.</given-names></name><name><surname>Zhang</surname><given-names>G.</given-names></name><name><surname>Jin</surname><given-names>Z.</given-names></name><name><surname>Stoppel</surname><given-names>D. C.</given-names></name><name><surname>Anderson</surname><given-names>M. P.</given-names></name></person-group> (<year>2011</year>). <article-title>Increased gene dosage of Ube3a results in autism traits and decreased glutamate synaptic transmission in mice</article-title>. <source/>Sci. Transl. Med.
<volume>3</volume>:<fpage>103ra197</fpage>. <pub-id pub-id-type="doi">10.1126/scitranslmed.3002627</pub-id><pub-id pub-id-type="pmid">21974935</pub-id></mixed-citation>
</ref>
<ref id="B106">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Steward</surname><given-names>O.</given-names></name><name><surname>Worley</surname><given-names>P. F.</given-names></name></person-group> (<year>2001</year>). <article-title>Selective targeting of newly synthesized Arc mRNA to active synapses requires NMDA receptor activation</article-title>. <source/>Neuron
<volume>30</volume>, <fpage>227</fpage>–<lpage>240</lpage>. <pub-id pub-id-type="doi">10.1016/s0896-6273(01)00275-6</pub-id><pub-id pub-id-type="pmid">11343657</pub-id></mixed-citation>
</ref>
<ref id="B107">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sullivan</surname><given-names>P. F.</given-names></name><name><surname>Kendler</surname><given-names>K. S.</given-names></name><name><surname>Neale</surname><given-names>M. C.</given-names></name></person-group> (<year>2003</year>). <article-title>Schizophrenia as a complex trait: evidence from a meta-analysis of twin studies</article-title>. <source/>Arch. Gen. Psychiatry
<volume>60</volume>, <fpage>1187</fpage>–<lpage>1192</lpage>. <pub-id pub-id-type="doi">10.1001/archpsyc.60.12.1187</pub-id><pub-id pub-id-type="pmid">14662550</pub-id></mixed-citation>
</ref>
<ref id="B108">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Swerdlow</surname><given-names>N. R.</given-names></name><name><surname>Weber</surname><given-names>M.</given-names></name><name><surname>Qu</surname><given-names>Y.</given-names></name><name><surname>Light</surname><given-names>G. A.</given-names></name><name><surname>Braff</surname><given-names>D. L.</given-names></name></person-group> (<year>2008</year>). <article-title>Realistic expectations of prepulse inhibition in translational models for schizophrenia research</article-title>. <source/>Psychopharmacology (Berl)
<volume>199</volume>, <fpage>331</fpage>–<lpage>388</lpage>. <pub-id pub-id-type="doi">10.1007/s00213-008-1072-4</pub-id><pub-id pub-id-type="pmid">18568339</pub-id></mixed-citation>
</ref>
<ref id="B109">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Takagi</surname><given-names>S.</given-names></name><name><surname>Balu</surname><given-names>D. T.</given-names></name><name><surname>Coyle</surname><given-names>J. T.</given-names></name></person-group> (<year>2015</year>). <article-title>Subchronic pharmacological and chronic genetic NMDA receptor hypofunction differentially regulate the Akt signaling pathway and Arc expression in juvenile and adult mice</article-title>. <source/>Schizophr. Res.
<volume>162</volume>, <fpage>216</fpage>–<lpage>221</lpage>. <pub-id pub-id-type="doi">10.1016/j.schres.2014.12.034</pub-id><pub-id pub-id-type="pmid">25592804</pub-id></mixed-citation>
</ref>
<ref id="B110">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Takao</surname><given-names>K.</given-names></name><name><surname>Kobayashi</surname><given-names>K.</given-names></name><name><surname>Hagihara</surname><given-names>H.</given-names></name><name><surname>Ohira</surname><given-names>K.</given-names></name><name><surname>Shoji</surname><given-names>H.</given-names></name><name><surname>Hattori</surname><given-names>S.</given-names></name><etal></etal></person-group>. (<year>2013</year>). <article-title>Deficiency of schnurri-2, an MHC enhancer binding protein, induces mild chronic inflammation in the brain and confers molecular, neuronal, and behavioral phenotypes related to schizophrenia</article-title>. <source/>Neuropsychopharmacology
<volume>38</volume>, <fpage>1409</fpage>–<lpage>1425</lpage>. <pub-id pub-id-type="doi">10.1038/npp.2013.38</pub-id><pub-id pub-id-type="pmid">23389689</pub-id></mixed-citation>
</ref>
<ref id="B111">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tzingounis</surname><given-names>A. V.</given-names></name><name><surname>Nicoll</surname><given-names>R. A.</given-names></name></person-group> (<year>2006</year>). <article-title>Arc/Arg3.1: linking gene expression to synaptic plasticity and memory</article-title>. <source/>Neuron
<volume>52</volume>, <fpage>403</fpage>–<lpage>407</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuron.2006.10.016</pub-id><pub-id pub-id-type="pmid">17088207</pub-id></mixed-citation>
</ref>
<ref id="B112">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van den Buuse</surname><given-names>M.</given-names></name></person-group> (<year>2010</year>). <article-title>Modeling the positive symptoms of schizophrenia in genetically modified mice: pharmacology and methodology aspects</article-title>. <source/>Schizophr. Bull.
<volume>36</volume>, <fpage>246</fpage>–<lpage>270</lpage>. <pub-id pub-id-type="doi">10.1093/schbul/sbp132</pub-id><pub-id pub-id-type="pmid">19900963</pub-id></mixed-citation>
</ref>
<ref id="B113">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vazdarjanova</surname><given-names>A.</given-names></name><name><surname>Ramirez-Amaya</surname><given-names>V.</given-names></name><name><surname>Insel</surname><given-names>N.</given-names></name><name><surname>Plummer</surname><given-names>T. K.</given-names></name><name><surname>Rosi</surname><given-names>S.</given-names></name><name><surname>Chowdhury</surname><given-names>S.</given-names></name><etal></etal></person-group>. (<year>2006</year>). <article-title>Spatial exploration induces ARC, a plasticity-related immediate-early gene, only in calcium/calmodulin-dependent protein kinase II-positive principal excitatory and inhibitory neurons of the rat forebrain</article-title>. <source/>J. Comp. Neurol.
<volume>498</volume>, <fpage>317</fpage>–<lpage>329</lpage>. <pub-id pub-id-type="doi">10.1002/cne.21003</pub-id><pub-id pub-id-type="pmid">16871537</pub-id></mixed-citation>
</ref>
<ref id="B114">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>H.</given-names></name><name><surname>Ardiles</surname><given-names>A. O.</given-names></name><name><surname>Yang</surname><given-names>S.</given-names></name><name><surname>Tran</surname><given-names>T.</given-names></name><name><surname>Posada-Duque</surname><given-names>R.</given-names></name><name><surname>Valdivia</surname><given-names>G.</given-names></name><etal></etal></person-group>. (<year>2016</year>). <article-title>Metabotropic glutamate receptors induce a form of LTP controlled by translation and Arc signaling in the hippocampus</article-title>. <source/>J. Neurosci.
<volume>36</volume>, <fpage>1723</fpage>–<lpage>1729</lpage>. <pub-id pub-id-type="doi">10.1523/JNEUROSCI.0878-15.2016</pub-id><pub-id pub-id-type="pmid">26843652</pub-id></mixed-citation>
</ref>
<ref id="B115">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Waung</surname><given-names>M. W.</given-names></name><name><surname>Pfeiffer</surname><given-names>B. E.</given-names></name><name><surname>Nosyreva</surname><given-names>E. D.</given-names></name><name><surname>Ronesi</surname><given-names>J. A.</given-names></name><name><surname>Huber</surname><given-names>K. M.</given-names></name></person-group> (<year>2008</year>). <article-title>Rapid translation of Arc/Arg3.1 selectively mediates mGluR-dependent LTD through persistent increases in AMPAR endocytosis rate</article-title>. <source/>Neuron
<volume>59</volume>, <fpage>84</fpage>–<lpage>97</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuron.2008.05.014</pub-id><pub-id pub-id-type="pmid">18614031</pub-id></mixed-citation>
</ref>
<ref id="B116">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weinstein</surname><given-names>J. J.</given-names></name><name><surname>Chohan</surname><given-names>M. O.</given-names></name><name><surname>Slifstein</surname><given-names>M.</given-names></name><name><surname>Kegeles</surname><given-names>L. S.</given-names></name><name><surname>Moore</surname><given-names>H.</given-names></name><name><surname>Abi-Dargham</surname><given-names>A.</given-names></name></person-group> (<year>2017</year>). <article-title>Pathway-specific dopamine abnormalities in schizophrenia</article-title>. <source/>Biol. Psychiatry
<volume>81</volume>, <fpage>31</fpage>–<lpage>42</lpage>. <pub-id pub-id-type="doi">10.1016/j.biopsych.2016.03.2104</pub-id><pub-id pub-id-type="pmid">27206569</pub-id></mixed-citation>
</ref>
<ref id="B117">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wiedholz</surname><given-names>L. M.</given-names></name><name><surname>Owens</surname><given-names>W. A.</given-names></name><name><surname>Horton</surname><given-names>R. E.</given-names></name><name><surname>Feyder</surname><given-names>M.</given-names></name><name><surname>Karlsson</surname><given-names>R. M.</given-names></name><name><surname>Hefner</surname><given-names>K.</given-names></name><etal></etal></person-group>. (<year>2008</year>). <article-title>Mice lacking the AMPA GluR1 receptor exhibit striatal hyperdopaminergia and ‘schizophrenia-related’ behaviors</article-title>. <source/>Mol. Psychiatry
<volume>13</volume>, <fpage>631</fpage>–<lpage>640</lpage>. <pub-id pub-id-type="doi">10.1038/sj.mp.4002056</pub-id><pub-id pub-id-type="pmid">17684498</pub-id></mixed-citation>
</ref>
<ref id="B118">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Williams</surname><given-names>C. A.</given-names></name><name><surname>Driscoll</surname><given-names>D. J.</given-names></name><name><surname>Dagli</surname><given-names>A. I.</given-names></name></person-group> (<year>2010</year>). <article-title>Clinical and genetic aspects of Angelman syndrome</article-title>. <source/>Genet. Med.
<volume>12</volume>, <fpage>385</fpage>–<lpage>395</lpage>. <pub-id pub-id-type="doi">10.1097/GIM.0b013e3181def138</pub-id><pub-id pub-id-type="pmid">20445456</pub-id></mixed-citation>
</ref>
<ref id="B119">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Winterer</surname><given-names>G.</given-names></name><name><surname>Weinberger</surname><given-names>D. R.</given-names></name></person-group> (<year>2004</year>). <article-title>Genes, dopamine and cortical signal-to-noise ratio in schizophrenia</article-title>. <source/>Trends Neurosci.
<volume>27</volume>, <fpage>683</fpage>–<lpage>690</lpage>. <pub-id pub-id-type="doi">10.1016/j.tins.2004.08.002</pub-id><pub-id pub-id-type="pmid">15474169</pub-id></mixed-citation>
</ref>
<ref id="B120">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>J.</given-names></name><name><surname>Petralia</surname><given-names>R. S.</given-names></name><name><surname>Kurushima</surname><given-names>H.</given-names></name><name><surname>Patel</surname><given-names>H.</given-names></name><name><surname>Jung</surname><given-names>M. Y.</given-names></name><name><surname>Volk</surname><given-names>L.</given-names></name><etal></etal></person-group>. (<year>2011</year>). <article-title>Arc/Arg3.1 regulates an endosomal pathway essential for activity-dependent β-amyloid generation</article-title>. <source/>Cell
<volume>147</volume>, <fpage>615</fpage>–<lpage>628</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2011.09.036</pub-id><pub-id pub-id-type="pmid">22036569</pub-id></mixed-citation>
</ref>
<ref id="B121">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ye</surname><given-names>Y.</given-names></name><name><surname>Mastwal</surname><given-names>S.</given-names></name><name><surname>Cao</surname><given-names>V. Y.</given-names></name><name><surname>Ren</surname><given-names>M.</given-names></name><name><surname>Liu</surname><given-names>Q.</given-names></name><name><surname>Zhang</surname><given-names>W.</given-names></name><etal></etal></person-group>. (<year>2016</year>). <article-title>Dopamine is required for activity-dependent amplification of Arc mRNA in developing postnatal frontal cortex</article-title>. <source/>Cereb. Cortex [Epub ahead of print]. <pub-id pub-id-type="doi">10.1093/cercor/bhw181</pub-id><pub-id pub-id-type="pmid">27365296</pub-id></mixed-citation>
</ref>
<ref id="B122">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>W.</given-names></name><name><surname>Wu</surname><given-names>J.</given-names></name><name><surname>Ward</surname><given-names>M. D.</given-names></name><name><surname>Yang</surname><given-names>S.</given-names></name><name><surname>Chuang</surname><given-names>Y. A.</given-names></name><name><surname>Xiao</surname><given-names>M.</given-names></name><etal></etal></person-group>. (<year>2015</year>). <article-title>Structural basis of arc binding to synaptic proteins: implications for cognitive disease</article-title>. <source/>Neuron
<volume>86</volume>, <fpage>490</fpage>–<lpage>500</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuron.2015.03.030</pub-id><pub-id pub-id-type="pmid">25864631</pub-id></mixed-citation>
</ref>
<ref id="B123">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>H.</given-names></name><name><surname>Nyholt</surname><given-names>D. R.</given-names></name></person-group> (<year>2017</year>). <article-title>Gene-based analyses reveal novel genetic overlap and allelic heterogeneity across five major psychiatric disorders</article-title>. <source/>Hum. Genet.
<volume>136</volume>, <fpage>263</fpage>–<lpage>274</lpage>. <pub-id pub-id-type="doi">10.1007/s00439-016-1755-6</pub-id><pub-id pub-id-type="pmid">28035465</pub-id></mixed-citation>
</ref>
</ref-list>
</back>
</article>
</pmc-articleset>